

# **Vietnam Pharmaceutical Corporation**

Consolidated financial statements

For the year ended 31 December 2025




**Shape the future  
with confidence**

# Vietnam Pharmaceutical Corporation

## CONTENTS

	<i>Pages</i>
General information	1 - 2
Report of management	3
Independent auditors' report	4 - 5
Consolidated balance sheet	6 - 7
Consolidated income statement	8 - 9
Consolidated cash flow statement	10 - 11
Notes to the consolidated financial statements	12 - 57



# Vietnam Pharmaceutical Corporation

## GENERAL INFORMATION

### THE CORPORATION

Vietnam Pharmaceutical Corporation ("the Corporation") was transformed from a state-owned one-member limited liability company to a joint stock company from 8 December 2016 in pursuant to the Enterprise Registration Certificate for joint stock company No. 0100109385 issued by Hanoi Department of Planning and Investment (now known as the Department of Finance), with the 8<sup>th</sup> amendment dated 16 September 2025 as the latest.

The principal activities in the current year of the Corporation are presented in Note 1 - General information of the Corporation – of the Notes to the consolidated financial statements.

The Corporation has a head office located at 12 Ngo Tat To, Van Mieu – Quoc Tu Giam ward, Hanoi, Vietnam and a representative office located at 126A Tran Quoc Thao street, Xuan Hoa ward, Ho Chi Minh city, Vietnam.

### BOARD OF DIRECTORS

Members of the Board of Directors during the year and at the date of this report are:

Mr. Dinh Xuan Han	Chairman	
Mr. Nguyen Tien Dung	Vice Chairman	Appointed on 21 April 2025
Mr. Tran Duc Hung	Vice Chairman	Resigned on 21 April 2025
Ms. Han Thi Khanh Vinh	Member	
Mr. Tran Van Hai	Member	
Mr. Do Manh Cuong	Independent member	

### AUDIT COMMITTEE

Members of the Audit Committee during the year and at the date of this report are:

Mr. Do Manh Cuong	Head	
Mr. Nguyen Tien Dung	Member	Appointed on 21 April 2025
Mr. Tran Duc Hung	Member	Resigned on 21 April 2025

### INTERNAL AUDIT

Members of the Internal Audit during the year and at the date of this report are:

Mr. Bui Tien Thao	Head	Appointed on 29 September 2025
Ms. Nguyen Thuy Dung	Head	Resigned on 1 July 2025
Ms. Nguyen Thi Thuy	Deputy Head	
Mr. Phi Ngoc Tu	Member	



# Vietnam Pharmaceutical Corporation

## GENERAL INFORMATION (continued)

### MANAGEMENT

Member of the Management during the year and at the date of this report is:

Ms. Han Thi Khanh Vinh                      General Director

### LEGAL REPRESENTATIVE

The legal representative of the Corporation during the year and at the date of this report is Ms. Han Thi Khanh Vinh – General Director.

### AUDITOR

The auditor of the Corporation is Ernst & Young Vietnam Limited.

# Vietnam Pharmaceutical Corporation

## REPORT OF MANAGEMENT

The Management of Vietnam Pharmaceutical Corporation ("the Corporation") is pleased to present this report and the consolidated financial statements of the Corporation and its subsidiaries for the year ended 31 December 2025.

### THE MANAGEMENT'S RESPONSIBILITY IN RESPECT OF THE CONSOLIDATED FINANCIAL STATEMENTS

The Management is responsible for the consolidated financial statements of each financial year which give a true and fair view of the consolidated financial position of the Corporation and its subsidiaries, and of the consolidated results of its operations and its consolidated cash flows for the year. In preparing those consolidated financial statements, the Management is required to:

- ▶ select suitable accounting policies and then apply them consistently;
- ▶ make judgments and estimates that are reasonable and prudent;
- ▶ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the consolidated financial statements; and
- ▶ prepare the consolidated financial statements on the going concern basis unless it is inappropriate to presume that the Corporation and its subsidiaries will continue their business.

The Management is responsible for ensuring that proper accounting records are kept which disclose, with reasonable accuracy at any time, the consolidated financial position of the Corporation and its subsidiaries and to ensure that the accounting records comply with the applied accounting system. It is also responsible for safeguarding the assets of the Corporation and its subsidiaries and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Management confirmed that it has complied with the above requirements in preparing the accompanying consolidated financial statements.

### STATEMENT BY THE MANAGEMENT

The Management does hereby state that, in its opinion, the accompanying consolidated financial statements give a true and fair view of the consolidated financial position of the Corporation and its subsidiaries as at 31 December 2025, and of the consolidated results of its operations and its consolidated cash flows for the year then ended in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the consolidated financial statements. 2



Han Thi Khanh Vinh  
General Director

Hanoi, Vietnam

30 March 2026



Shape the future  
with confidence

Ernst & Young Vietnam Limited  
2 Hai Trieu Street, Sai Gon Ward  
Ho Chi Minh City, Vietnam

Tel: +84 28 3824 5252  
Email: eyhcmc@vn.ey.com  
Website (EN): ey.com/en\_vn  
Website (VN): ey.com/vi\_vn

Reference: 12315195/68672637 - HN

## INDEPENDENT AUDITORS' REPORT

**To: The Shareholders of Vietnam Pharmaceutical Corporation**

We have audited the accompanying consolidated financial statements of Vietnam Pharmaceutical Corporation ("the Corporation") and its subsidiaries as prepared on 30 March 2026 and set out on pages 6 to 57, which comprise the consolidated balance sheet as at 31 December 2025, the consolidated income statement and the consolidated cash flow statement for the year then ended and the notes thereto.

### *Management's responsibility*

Management is responsible for the preparation and true and fair presentation of these consolidated financial statements in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the consolidated financial statements, and for such internal control as management determines is necessary to enable the preparation and presentation of the consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### *Auditors' responsibility*

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the Corporation and its subsidiaries' preparation and true and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation and its subsidiaries' internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

22.  
TY  
4  
YOU  
NA  
40 C



Shape the future  
with confidence

### Opinion

In our opinion, the consolidated financial statements give a true and fair view, in all material respects, of the consolidated financial position of the Corporation and its subsidiaries as at 31 December 2025, and of the consolidated results of its operations and its consolidated cash flows for the year then ended in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the consolidated financial statements.

Ernst & Young Vietnam Limited



Bùi Anh Tuấn  
Deputy General Director  
Audit Practising Registration  
Certificate No. 1067-2023-004-1

Le Minh Tung  
Auditor  
Audit Practising Registration  
Certificate No. 4656-2023-004-1

Hanoi, Vietnam

30 March 2026

# Vietnam Pharmaceutical Corporation

B01-DN/HN

CONSOLIDATED BALANCE SHEET  
as at 31 December 2025

Currency: VND

Code	ASSETS	Notes	Ending balance	Beginning balance
<b>100</b>	<b>A. CURRENT ASSETS</b>		<b>4,709,841,689,926</b>	<b>4,363,155,594,686</b>
<b>110</b>	<b>I. Cash and cash equivalent</b>	<b>5</b>	<b>91,326,179,936</b>	<b>289,066,457,419</b>
111	1. Cash		43,426,179,936	38,216,457,419
112	2. Cash equivalent		47,900,000,000	250,850,000,000
<b>120</b>	<b>II. Short-term investments</b>		<b>644,080,000,000</b>	<b>755,670,000,000</b>
121	1. Held-for-trading securities		-	50,000,000
123	2. Held-to-maturity investments	6	644,080,000,000	755,620,000,000
<b>130</b>	<b>III. Current accounts receivable</b>		<b>1,915,751,290,792</b>	<b>1,645,686,451,677</b>
131	1. Short-term trade receivables	7.1	1,844,427,761,462	1,584,946,177,850
132	2. Short-term advances to suppliers	7.2	23,923,451,679	31,594,615,967
136	3. Other short-term receivables	8	106,660,599,802	70,199,563,270
137	4. Provision for doubtful short-term receivables	7.3	(59,260,522,151)	(41,053,905,410)
<b>140</b>	<b>IV. Inventories</b>	<b>10</b>	<b>2,003,137,320,518</b>	<b>1,633,236,624,658</b>
141	1. Inventories		2,015,841,959,957	1,662,817,347,953
149	2. Provision for obsolete inventories		(12,704,639,439)	(29,580,723,295)
<b>150</b>	<b>V. Other current assets</b>		<b>55,546,898,680</b>	<b>39,496,060,932</b>
151	1. Short-term prepaid expenses		1,970,228,470	2,952,155,410
152	2. Value-added tax deductible		46,279,129,720	34,106,724,260
153	3. Tax and other receivables from the State	17	7,297,540,490	2,437,181,262
<b>200</b>	<b>B. NON-CURRENT ASSETS</b>		<b>2,942,628,272,225</b>	<b>2,092,302,291,116</b>
<b>210</b>	<b>I. Long-term receivables</b>		<b>1,402,147,510</b>	<b>708,299,536</b>
216	1. Other long-term receivables		1,402,147,510	708,299,536
<b>220</b>	<b>II. Fixed assets</b>		<b>267,648,302,707</b>	<b>281,174,501,833</b>
221	1. Tangible fixed assets	11	163,916,255,352	174,474,438,246
222	Cost		514,211,409,778	518,506,151,736
223	Accumulated depreciation		(350,295,154,426)	(344,031,713,490)
227	2. Intangible fixed assets	12	103,732,047,355	106,700,063,587
228	Cost		128,887,069,845	129,518,873,145
229	Accumulated amortization		(25,155,022,490)	(22,818,809,558)
<b>230</b>	<b>III. Investment properties</b>	<b>13</b>	<b>34,779,306,191</b>	<b>35,759,475,749</b>
231	1. Cost		45,821,328,558	45,821,328,558
232	2. Accumulated depreciation		(11,042,022,367)	(10,061,852,809)
<b>240</b>	<b>IV. Long-term assets in progress</b>		<b>4,053,919,259</b>	<b>800,200,000</b>
242	1. Construction in progress		4,053,919,259	800,200,000
<b>250</b>	<b>V. Long-term investments</b>	<b>14</b>	<b>2,602,522,694,840</b>	<b>1,738,533,518,151</b>
252	1. Investments in associates		2,032,899,478,459	987,874,650,144
253	2. Investments in other entities		697,823,455,837	870,823,455,837
254	3. Provision for long-term financial investments		(140,200,239,456)	(120,164,587,830)
255	4. Held-to-maturity investments	6	12,000,000,000	-
<b>260</b>	<b>VI. Other long-term assets</b>		<b>32,221,901,718</b>	<b>35,326,295,847</b>
261	1. Long-term prepaid expenses	15	29,693,176,746	30,710,483,029
262	2. Deferred tax assets	30.3	2,528,724,972	4,615,812,818
<b>270</b>	<b>TOTAL ASSETS</b>		<b>7,652,469,962,151</b>	<b>6,455,457,885,802</b>

CONSOLIDATED BALANCE SHEET (continued)  
as at 31 December 2025

Currency: VND

Code	RESOURCES	Notes	Ending balance	Beginning balance
<b>300</b>	<b>C. LIABILITIES</b>		<b>3,620,798,780,130</b>	<b>2,945,521,946,922</b>
<b>310</b>	<b>I. Current liabilities</b>		<b>3,589,102,670,962</b>	<b>2,914,045,605,262</b>
311	1. Short-term trade payables	16.1	1,850,633,356,610	1,555,881,211,506
312	2. Short-term advances from customers	16.2	39,419,574,691	22,610,280,609
313	3. Statutory obligations	17	23,524,530,412	52,276,416,801
314	4. Payables to employees		32,638,709,616	26,686,757,010
315	5. Short-term accrued expenses	18	12,234,035,829	10,469,639,652
318	6. Short-term unearned revenues		2,502,062,275	2,366,571,045
319	7. Other short-term payables	19	17,421,514,208	21,093,076,654
320	8. Short-term loans	21	1,587,760,969,107	1,207,514,630,352
321	9. Short-term provisions		1,092,549,250	-
322	10. Bonus and welfare fund	20	21,875,368,964	15,147,021,633
<b>330</b>	<b>II. Non-current liabilities</b>		<b>31,696,109,168</b>	<b>31,476,341,660</b>
336	1. Long-term unearned revenues		148,931,932	198,575,812
337	2. Other long-term payables		1,750,000,000	1,082,000,000
338	3. Long-term loans	21	29,797,177,236	30,195,765,848
<b>400</b>	<b>D. OWNERS' EQUITY</b>		<b>4,031,671,182,021</b>	<b>3,509,935,938,880</b>
<b>410</b>	<b>I. Capital</b>	<b>22</b>	<b>4,031,671,182,021</b>	<b>3,509,935,938,880</b>
411	1. Issued share capital		2,370,000,000,000	2,370,000,000,000
411a	- Shares with voting rights		2,370,000,000,000	2,370,000,000,000
414	2. Other owners' capital		57,597,010,408	57,597,010,408
416	3. Asset revaluation reserve		(366,766,560,611)	(388,400,444,386)
417	4. Foreign exchange differences reserve		-	(9,010,862)
418	5. Investment and development fund		417,701,058,585	416,297,582,809
420	6. Other funds belonging to owners' equity		982,723,327	982,723,327
421	7. Undistributed earnings		1,260,582,734,866	792,862,397,827
421a	- Undistributed earnings by the end of prior year		521,983,651,047	376,684,564,188
421b	- Undistributed earnings of the current year		738,599,083,819	416,177,833,639
429	8. Non-controlling interests		291,574,215,446	260,605,679,757
<b>440</b>	<b>TOTAL LIABILITIES AND OWNERS' EQUITY</b>		<b>7,652,469,962,151</b>	<b>6,455,457,885,802</b>



Nguyen Thi Hang  
Preparer



Lu Thi Khanh Tran  
Chief Accountant



Hanoi, Vietnam  
30 March 2026

Han Thi Khanh Vinh  
General Director

CONSOLIDATED INCOME STATEMENT  
for the year ended 31 December 2025

Currency: VND

Code	ITEMS	Notes	Current year	Previous year
01	1. Revenue from sale of goods and rendering of services	24.1	5,674,802,482,975	5,529,361,265,970
02	2. Deductions	24.1	(29,208,672,409)	(7,559,820,824)
10	3. Net revenue from sale of goods and rendering of services	24.1	5,645,593,810,566	5,521,801,445,146
11	4. Cost of goods sold and services rendered	25	(5,092,394,957,721)	(4,929,091,343,194)
20	5. Gross profit from sale of goods and rendering of services		553,198,852,845	592,710,101,952
21	6. Finance income	24.2	262,849,469,202	258,183,825,320
22	7. Finance expenses	26	(120,763,502,510)	(103,707,004,784)
23	In which: Interest expenses		(67,308,431,064)	(53,512,208,376)
24	8. Share of profit of associates	14.1	503,926,781,242	158,812,167,035
25	9. Selling expenses	27	(277,204,063,654)	(273,971,995,546)
26	10. General and administrative expenses	27	(133,621,032,954)	(148,968,624,888)
30	11. Operating profit		788,386,504,171	483,058,469,089
31	12. Other income	29	43,514,681,898	32,233,029,195
32	13. Other expenses	29	(7,118,890,072)	(6,059,591,347)
40	14. Other profit	29	36,395,791,826	26,173,437,848
50	15. Accounting profit before tax		824,782,295,997	509,231,906,937
51	16. Current corporate income tax expenses	30.1	(31,879,281,718)	(37,257,614,229)
52	17. Deferred tax expenses	30.3	(2,087,087,846)	(3,879,165,953)
60	18. Net profit after tax		790,815,926,433	468,095,126,755
61	19. Net profit after tax attributable to shareholders of the parent		738,599,083,819	420,814,703,639
62	20. Net profit after tax attributable to non-controlling interests		52,216,842,614	47,280,423,116

CONSOLIDATED INCOME STATEMENT (continued)  
for the year ended 31 December 2025

Currency: VND

Code	ITEMS	Notes	Current year	Previous year (Restated)
70	21. Basic earnings per share	32	3,071	1,710
71	22. Diluted earnings per share	32	3,071	1,710

Hanoi, Vietnam  
30 March 2026



Nguyen Thi Hang  
Preparer



Lu Thi Khanh Tran  
Chief Accountant



Han Thi Khanh Vinh  
General Director

CONSOLIDATED CASH FLOW STATEMENT  
for the year ended 31 December 2025

Currency: VND

Code	ITEMS	Notes	Current year	Previous year
	<b>I. CASH FLOWS FROM OPERATING ACTIVITIES</b>			
01	<b>Accounting profit before tax</b>		<b>824,782,295,997</b>	<b>509,231,906,937</b>
	<i>Adjustments for:</i>			
02	Depreciation of tangible fixed assets and investment properties, amortization of intangible fixed assets and allocated prepaid land rental fee		28,797,277,868	30,287,335,588
03	Provisions/(reversal of provisions)		22,458,733,761	(23,133,111,141)
04	Foreign exchange losses arisen from revaluation of monetary accounts denominated in foreign currencies		1,350,791,078	3,572,992,533
05	Profits from investing activities		(701,632,959,858)	(393,977,695,232)
06	Interest expenses	26	67,308,431,064	53,512,208,376
08	<b>Operating profit before changes in working capital</b>		<b>243,064,569,910</b>	<b>179,493,637,061</b>
09	(Increase)/decrease in receivables		(319,923,603,295)	107,313,509,153
10	Increase in inventories		(353,024,612,004)	(208,470,338,487)
11	Increase/(decrease) in payables		307,503,490,782	(96,418,199,292)
12	Decrease/(increase) in prepaid expenses		977,986,951	(330,907,582)
13	Decrease in held-for-trading securities		50,000,000	-
14	Interest paid		(66,010,807,446)	(54,272,979,989)
15	Corporate income tax paid	17	(60,325,177,808)	(46,478,013,595)
17	Other cash outflows from operating activities	20	(8,166,105,961)	(16,351,232,784)
20	<b>Net cash flows used in operating activities</b>		<b>(255,854,258,871)</b>	<b>(135,514,525,515)</b>
	<b>II. CASH FLOWS FROM INVESTING ACTIVITIES</b>			
21	Purchase, construction of fixed assets and other long-term assets		(14,998,273,448)	(8,159,728,768)
22	Proceeds from disposals of fixed assets and other long-term assets		1,131,271,968	23,704,343,391
23	Loans to other entities and payments for purchase of debt instruments of other entities		(698,500,000,000)	(1,036,120,000,000)
24	Collections from borrowers and proceeds from sale of debt instruments of other entities		798,040,000,000	1,203,700,000,000
25	Payments for investment in other entities		(494,777,000,000)	-
26	Proceeds from sale of investments in other entities		27,274,114,505	-
27	Interest and dividends received		311,972,482,050	252,996,496,785
30	<b>Net cash flows (used in)/from investing activities</b>		<b>(69,857,404,925)</b>	<b>436,121,111,408</b>

CONSOLIDATED CASH FLOW STATEMENT (continued)  
for the year ended 31 December 2025

Currency: VND

Code	ITEMS	Notes	Current year	Previous year
	<b>III. CASH FLOWS FROM FINANCING ACTIVITIES</b>			
33	Drawdown of borrowings		4,618,363,333,105	3,518,443,336,598
34	Repayment of borrowings		(4,238,515,582,962)	(3,448,112,409,136)
36	Dividends paid, profit distributed to equity holders of the parent and non-controlling interests		(251,853,721,488)	(185,840,109,719)
40	<b>Net cash flows from/(used in) financing activities</b>		<b>127,994,028,655</b>	<b>(115,509,182,257)</b>
50	<b>Net (decrease)/ increase in cash for the year</b>		<b>(197,717,635,141)</b>	<b>185,097,403,636</b>
60	<b>Cash and cash equivalents at the beginning of the year</b>		<b>289,066,457,419</b>	<b>104,326,275,471</b>
61	Impact of exchange rate fluctuation		(22,642,342)	(357,221,688)
70	<b>Cash and cash equivalents at the end of the year</b>	<b>5</b>	<b>91,326,179,936</b>	<b>289,066,457,419</b>



Nguyen Thi Hang  
Preparer



Lu Thi Khanh Tran  
Chief Accountant



Hanoi, Vietnam  
30 March 2026

Han Thi Khanh Vinh  
General Director

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
as at 31 December 2025 and for the year then ended

**1. GENERAL INFORMATION OF THE CORPORATION**

Vietnam Pharmaceutical Corporation ("the Corporation") was transformed from a state owned one-member limited liability company to a joint stock company from 8 December 2016 in pursuant to the Enterprise Registration Certificate for joint stock company No. 0100109385 issued by Hanoi Department of Planning and Investment (now known as the Department of Finance), with the 8<sup>th</sup> amendment dated 16 September 2025 as the latest.

The principal activities of the Corporation and its subsidiaries are:

- ▶ Wholesale of perfume, cosmetics and hygiene products (except cosmetics which are harmful to people's health);
- ▶ Manufacture of drugs, pharmaceutical chemical products, medicines;
- ▶ Provision of drugs preservation service, drugs import-export service, import-export of products which the Corporation and its subsidiaries trade; testing of drugs, cosmetics and functional foods;
- ▶ Provision of technology transfer services;
- ▶ Manufacture of functional foods, food additives, sterilization substances for human;
- ▶ Trade of chemicals (except chemicals prohibited by the Government);
- ▶ Manufacture of cosmetics, soaps, detergents, polishes and hygiene products (except cosmetics which are harmful to people's health);
- ▶ Retail of drugs, medical instruments, cosmetics and hygiene products in specialised shops;
- ▶ Trade of real estate, land use rights of land owners, land users or land lease;
- ▶ Advertising activities (except tobacco advertising);
- ▶ Printing and related services;
- ▶ Vocational training;
- ▶ Passenger transportation under contracts, tourist transportation by cars, cargo transportation by cars;
- ▶ Wholesale of medical machines and equipment;
- ▶ Manufacture of wrinkled papers, wrinkled boards, and packing from papers and boards; and
- ▶ Manufacture of medical, dental, orthopedic and rehabilitation equipment and instruments.

The Corporation has a head office located at 12 Ngo Tat To, Van Mieu – Quoc Tu Giam ward, Hanoi, Vietnam and a representative office located at 126A Tran Quoc Thao street, Xuan Hoa ward, Ho Chi Minh city, Vietnam.

The normal course of business cycle of the Corporation and its subsidiaries is 12 months.

The number of the Corporation and its subsidiaries' employees as at 31 December 2025 is 824 (31 December 2024: 867).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

1. GENERAL INFORMATION OF THE CORPORATION (continued)

*Corporate structure*

As at 31 December 2025, the Corporation has 3 subsidiaries (31 December 2024: 4 subsidiaries). Details on these subsidiaries and the Corporation's ownership interest in its subsidiaries are as follows:

No.	Name	Head office's address	Principal activities	Ending balance			Beginning balance		
				Capital contribution	Voting rights	Ownership and interest	Capital contribution	Voting rights	Ownership and interest
1	Codupha Central Pharmaceutical Joint Stock Company	262L Le Van Sy street, Nhieu Loc ward, Ho Chi Minh city	Importing, exporting and trading pharmaceuticals, medical equipment, instruments and cosmetics.	66.35%	66.57%	66.57%	66.35%	66.57%	66.57%
2	Central Pharmaceutical CPC1 Joint Stock Company	87 Nguyen Van Troi street, Phuong Liet ward, Hanoi	Wholesale and retail of drugs, medical instruments, cosmetics and hygiene products.	65.41%	65.41%	65.41%	65.41%	65.41%	65.41%
3	Central Pharmaceutical Joint Stock Company No.3	115 Ngo Gia Tu street, Hai Chau ward, Da Nang city	Manufacturing and trading pharmaceutical products, chemicals, cosmetics, nutritious food, medical machinery and equipment, pharmaceutical processing.	65.00%	66.81%	66.81%	65.00%	66.81%	66.81%
4	Codupha-Lao Pharmaceutical Company Limited (*)	253 Vieng Chaluen street, Saysetta, Vientiane, Laos	Manufacturing and trading pharmaceutical products	-	-	-	62.17%	93.70%	62.38%

(\*) The Corporation indirectly held interest and voting rights in this entity through Codupha Central Pharmaceutical Joint Stock Company. During the year, Codupha Central Pharmaceutical Joint Stock Company completed the disposal of its entire investment in this entity for a cash consideration of VND 6.74 billion. The difference between the consideration received and the net assets of this subsidiary at the disposal date is VND 5.1 billion and is recognized in Finance income of the consolidated income statement.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

## 2. BASIS OF PREPARATION

### 2.1 *Accounting standards and system*

The consolidated financial statements of the Corporation and its subsidiaries, which are expressed in Vietnam Dong ("VND"), are prepared in accordance with the Vietnamese Enterprise Accounting System as per Circular 200/2014/TT-BTC dated 22 December 2014 ("Circular 200"), Circular 202/2014/TT-BTC dated 22 December 2014 ("Circular 202") and Vietnamese Accounting Standard issued by the Ministry of Finance as per:

- ▶ Decision No. 149/2001/QĐ-BTC dated 31 December 2001 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 1);
- ▶ Decision No. 165/2002/QĐ-BTC dated 31 December 2002 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 2);
- ▶ Decision No. 234/2003/QĐ-BTC dated 30 December 2003 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 3);
- ▶ Decision No. 12/2005/QĐ-BTC dated 15 February 2005 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 4); and
- ▶ Decision No. 100/2005/QĐ-BTC dated 28 December 2005 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 5).

Accordingly, the accompanying consolidated financial statements, including their utilization are not designed for those who are not informed about Vietnam's accounting principles, procedures and practices and furthermore are not intended to present the consolidated financial position and consolidated results of operations and consolidated cash flows of the Corporation and its subsidiaries in accordance with accounting principles and practices generally accepted in countries other than Vietnam.

### 2.2 *Applied accounting documentation system*

The applied accounting documentation system of the Corporation and its subsidiaries is the General Journal system.

### 2.3 *Fiscal year*

The Corporation and its subsidiaries' fiscal year applicable for the preparation of its consolidated financial statements starts on 1 January and ends on 31 December.

### 2.4 *Accounting currency*

The consolidated financial statements are prepared in VND which is also the Corporation and its subsidiaries' accounting currency.

### 2.5 *Basis of consolidation*

The consolidated financial statements comprise the financial statements of the Corporation and its subsidiaries for the year ended 31 December 2025.

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Corporation obtains control, and continued to be consolidated until the date that such control ceases.

The financial statements of subsidiaries are prepared for the same reporting year as the parent company, using consistent accounting policies.

All intra-company balances, income and expenses and unrealized gains or losses resulting from intra-company transactions are eliminated in full.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**2. BASIS OF PREPARATION (continued)**

**2.5 Basis of consolidation (continued)**

Non-controlling interests represent the portion of profit or loss and net assets not held by the Corporation and are presented separately in the consolidated income statement and within equity in the consolidated balance sheet.

Impact of change in the ownership interest of a subsidiary, without a loss of control, is recorded in undistributed earning.

**2.6 Accounting regulation issued but not yet effective**

On 27 October 2025, the Ministry of Finance issued Circular No. 99/2025/TT-BTC providing guidance on the enterprise accounting regime ("Circular 99"), replacing Circular No. 200/2014/TT-BTC providing guidance on the enterprise accounting regime issued by the Ministry of Finance on 22 December 2014 and several other related regulations. Circular 99 takes effect from 1 January 2026 and applies to enterprises with a financial year beginning on or after 1 January 2026.

The Corporation and its subsidiaries are in the process of assessing the impact of Circular 99 on the preparation and presentation of the consolidated financial statements and will implement Circular 99 for the financial year ending 31 December 2026.

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**3.1 Cash and cash equivalents**

Cash and cash equivalents comprise cash on hand, cash in banks and short-term, highly liquid investments with an original maturity of not more than three months that are readily convertible into known amounts of cash and that are subject to an insignificant risk of change in value.

**3.2 Inventories**

Inventories are measured at their historical costs. The cost of inventories comprises costs of purchase, costs of conversion (including raw materials, direct labor cost, other directly related cost, manufacturing general overheads allocated based on the normal operating capacity) incurred in bringing the inventories to their present location and condition.

In case the net realizable value is lower than the original price, it must be calculated according to the net realizable value.

Net realizable value represents the estimated selling price in the ordinary course of business less the estimated costs to complete and the estimated costs necessary to make the sale.

The perpetual method is used to record inventories, which are valued as follows:

- |                                                    |   |                                                                                                                                                   |
|----------------------------------------------------|---|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Raw materials, tools and supplies, and merchandise | - | Cost of purchase on a weighted average basis.                                                                                                     |
|                                                    | - | Cost of merchandise purchase at Codupha Central Pharmaceutical Joint Stock Company on specific identification basis.                              |
| Finished goods and work-in-process                 | - | Cost of direct materials and labour plus attributable manufacturing overheads based on the normal operating capacity on a weighted average basis. |

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.2 Inventories (continued)**

*Provision for obsolete inventories*

An inventory provision is created for the estimated loss arising due to the impairment of value (through diminution, damage, obsolescence, etc.) of raw materials, finished goods, and other inventories owned by the Corporation and its subsidiaries, based on appropriate evidence of impairment available at the consolidated balance sheet date.

Increases or decreases to the provision balance are recorded into the cost of goods sold account in the consolidated income statement. When inventories are expired, obsolete, damage or become useless, the difference between the provision previously made and the historical cost of inventories are included in the consolidated income statement.

**3.3 Receivables**

Receivables are presented in the consolidated financial statements at the carrying amounts due from customers and other debtors, after provision for doubtful debts.

The provision for doubtful debts represents amounts of outstanding receivables of the Corporation and its subsidiaries at the balance sheet date which are doubtful of being recovered. Increases and decreases to the provision balance are recorded as general and administrative expense in the consolidated income statement. When bad debts are determined as unrecoverable and accountant writes off those bad debts, the differences between the provision for doubtful receivables previously made and historical cost of receivables are included in the consolidated income statement.

**3.4 Tangible fixed assets**

Tangible fixed assets are stated at cost less accumulated depreciation.

The cost of a tangible fixed asset comprises of its purchase price and any directly attributable costs of bringing the tangible fixed asset to working condition for its intended use or is at the revaluated amounts at the date of corporate valuation for the purpose of transformation to joint stock companies.

Expenditures for additions, improvements and renewals are added to the carrying amount of the assets and expenditures for maintenance and repairs are charged to the consolidated income statement as incurred.

When tangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the consolidated income statement.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.5 Leased assets**

The determination of whether an arrangement is, or contains a lease is based on the substance of the arrangement at inception date and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset and the arrangement conveys a right to use the asset.

A lease is classified as a finance lease whenever the terms of the lease transfer substantially all the risks and rewards of ownership of the asset to the lessee. All other leases are classified as operating leases.

*Where the Corporation and its subsidiaries are the lessees*

Lease expense is recognized in the consolidated income statement on a straight-line basis over the lease term.

*Where the Corporation and its subsidiaries are the lessors*

Assets subject to operating leases are included as fixed assets in the consolidated balance sheet. Initial direct costs incurred in negotiating an operating lease are recognized in the consolidated income statement as incurred.

Lease income is recognized in the consolidated income statement on a straight-line basis over the lease term.

**3.6 Intangible fixed assets**

Intangible assets are stated at cost less accumulated amortization.

The cost of an intangible fixed asset comprises of its purchase price and any directly attributable costs of preparing the intangible fixed asset for its intended use or is at the revaluated amounts at the date of corporate valuation for the purpose of transformation to joint stock companies.

Expenditures for additions, improvements are added to the carrying amount of the assets and other expenditures are charged to the consolidated income statement as incurred.

When intangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the consolidated income statement.

*Land use rights*

Land use rights comprise the indefinite land use rights and the prepayment for the land lease contracts which are effective prior to 2003 and for which, land use right certificates were issued. These land use rights are recorded as intangible fixed assets according to Circular No. 45/2013/TT-BTC issued by the Ministry of Finance on 25 April 2013 guiding the management, use and depreciation of fixed assets.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.7 Depreciation and amortization**

Depreciation of tangible fixed assets and amortization of intangible assets are calculated on a straight-line basis over the estimated useful life of each asset as follows:

Buildings and structures	5 - 59 years
Office equipment	2 - 12 years
Means of transportation	4 - 10 years
Machinery and equipment	2 - 12 years
Computer software	3 - 10 years
Definite land use rights	30 - 50 years

Infinite land use rights are not amortized.

**3.8 Investment properties**

Investment properties are stated at cost including transaction costs less accumulated depreciation. Investment properties held for capital appreciation are not depreciated but subject to impairment review.

Subsequent expenditure relating to an investment property that has already been recognized is added to the net book value of the investment property when it is probable that future economic benefits, in excess of the originally assessed standard of performance of the existing investment property, will flow to the Corporation.

Depreciation of investment properties are calculated on a straight-line basis over the estimated useful life of each asset as follows:

Buildings	9 - 46 years
-----------	--------------

Investment properties are derecognized when either they have been disposed of or when the investment properties are permanently withdrawn from use and no future economic benefit is expected from its disposal. The difference between the net disposal proceeds and the carrying amount of the assets is recognized in the consolidated income statement in the year of retirement or disposal.

Transfers are made to investment properties when, and only when, there is a change in use, evidenced by ending of owner-occupation, commencement of an operating lease to another party or ending of construction or development. Transfers are made from investment properties when, and only when, there is change in use, evidenced by commencement of owner-occupation or commencement of development with a view to sale. The transfer from investment property to owner-occupied property or inventories does not change the cost or the carrying value of the property for subsequent accounting at the date of change in use.

**3.9 Borrowing costs**

Borrowing costs consist of interest and other costs that the Corporation and its subsidiaries incur in connection with the borrowing of funds.

Borrowing costs are recorded as expense during the year in which they are incurred.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.10 Prepaid expenses**

Prepaid expenses are reported as short-term or long-term prepaid expenses on the consolidated balance sheet and amortized over the period for which the amounts are paid or the period in which economic benefits are generated in relation to these expenses.

*Prepaid land rental*

The prepaid land rental represents the unamortized balance of advance payment made in accordance with the lease contract signed with Department of Natural Resources and Environment of Da Nang City on 2 January 2016 for a period of 30 years from 2 January 2016; the lease contract signed with Tan Tao Investment & Industry JSC on 21 October 2005 and 21 February 2017 with the lease terms from 21 October 2005 to 21 October 2050 and from 21 February 2017 to 16 August 2050. In accordance with Circular 45/2013/TT-BTC dated 25 April 2013, such prepayments for land rental are recognized as long-term prepaid expenses and amortized over the remaining lease period.

**3.11 Investments**

*Investments in associates*

The Corporation and its subsidiaries' investments in its associates are accounted for using the equity method of accounting. An associate is an entity in which the Corporation and its subsidiaries have significant influence that is neither subsidiaries nor joint ventures. The Corporation and its subsidiaries generally deem they have significant influence if they have over 20% of the voting rights.

Under the equity method, the investment is carried in the consolidated balance sheet at cost plus post acquisition changes in the Corporation and its subsidiaries' share of net assets of the associates. Funds distributed from the associates are recognized in equity of the Corporation accordingly. Goodwill arising on acquisition of the associate is included in the carrying amount of the investment. Goodwill is not amortized and subject to annual review for impairment. The consolidated income statement reflects the share of the post-acquisition results of operations of the associates.

The share of post-acquisition profit/(loss) of the associates is presented on face of the consolidated income statement and its share of post-acquisition movements in reserves is recognized in reserves. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. Dividend/profit sharing received or receivable from associates reduces the carrying amount of the investment.

In addition, for the dividends/profits shared from undistributed earnings of associates arising before the date when the Corporation and its subsidiaries were officially transformed to joint stock companies, the Corporation recognizes an increase in asset revaluation reserve (see Note 3.14) and a decrease in undistributed earnings on the consolidated balance sheet.

The financial statements of the associates are prepared for the same reporting period and use the same accounting policies as the Corporation and its subsidiaries. Where necessary, adjustments are made to bring the accounting policies in line with those of the Corporation and its subsidiaries.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

#### 3.11 *Investments* (continued)

##### *Investments in other entities*

Investments in other entities are stated at their original costs according to the revaluated value at the date when the Corporation and its subsidiaries were officially transformed to joint stock companies. Dividends/profit shared from accumulated profits of other entities arising before the date when the Corporation and its subsidiaries were transformed to joint stock companies are deducted to the cost of the investment.

##### *Provision for diminution in value of the investments*

Provision of the investment is made when there are reliable evidence of the diminution in value of those investments at the consolidated balance sheet date.

Increases or decreases to the provision balance are recorded as finance expense in the consolidated income statement.

##### *Held-to-maturity investments*

Held-to-maturity investments are stated at their original costs. After initial recognition, held-to-maturity investments are measured at recoverable amount. Any impairment loss incurred is recognized as finance expense in the consolidated financial statements and deducted against the value of such investments.

#### 3.12 *Payables and accruals*

Payables and accruals are recognized for amounts to be paid in the future for goods and services received, whether or not billed to the Corporation and its subsidiaries.

#### 3.13 *Foreign currency transactions*

Transactions in currencies other than the Corporation and its subsidiaries' reporting currency (VND) are recorded at the actual transaction exchange rates at transaction dates which are determined as follows:

- ▶ Transactions resulting in receivables are recorded at the buying exchange rates of the commercial banks designated for collection;
- ▶ Transactions resulting in liabilities are recorded at the selling exchange rates of the commercial banks designated for payment; and
- ▶ Payments for assets or expenses without liabilities initially being recognized is recorded at the buying exchange rates of the commercial banks that process these payments.

At the end of the year, monetary balances denominated in foreign currencies are translated at the actual exchange rates at the balance sheet dates which are determined as follows:

- ▶ Monetary assets are translated at buying exchange rate of the commercial bank where the Corporation and its subsidiaries conduct transactions regularly; and
- ▶ Monetary liabilities are translated at selling exchange rate of the commercial bank where the Corporation and its subsidiaries conduct transactions regularly.

All foreign exchange differences incurred are taken to the consolidated income statement.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.13 Foreign currency transactions (continued)**

Conversion of the financial statements of a foreign operation for consolidation purpose is as follows:

- ▶ assets and liabilities are converted using the actual exchange rates at the balance sheet date;
- ▶ undistributed profit after tax arising after the acquisition of the subsidiary is converted according to revenue, expense items of the income statement;
- ▶ dividends paid are converted using the actual exchange rates at the date of dividends payment; and
- ▶ items in the income statement and cash flow statement are converted using average exchange rates of the year.

All foreign exchange differences resulting from conversion of financial statements of the subsidiary for the consolidation purpose are taken to the Foreign exchange differences reserve on the consolidated balance sheet and charged to the consolidated income statement upon the disposal of the investment.

**3.14 Share capital**

*Ordinary shares*

Ordinary shares are recognized at issuance price less incremental costs directly attributable to the issue of shares, net of tax effects. Such costs are recognized as a deduction from share premium.

*Difference arising from revaluation of equity investments*

For the purpose of corporate valuation for the transformation to a joint stock company, the Corporation exercised the revaluation of its investments in subsidiaries and associates and based on the valuation results approved by the authorized government agencies, the Corporation recognized investments in subsidiaries and associates according to the revalued amounts.

For the purpose of preparing the consolidated financial statements, the difference between the revalued investments in subsidiaries and associates and the previous carrying value is accounted for as a deduction to Asset revaluation reserve on the consolidated balance sheet. Dividends/profit shared before the date when the Corporation was transformed to a joint stock company are added to Asset revaluation reserve.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

#### 3.15 Appropriation of net profits

Net profit after tax is available for appropriation to shareholders after approval in the annual general meeting, and after making appropriation to reserve funds in accordance with the Charters of the Corporation and its subsidiaries and Vietnam's regulatory requirements.

The Corporation and its subsidiaries maintain the following reserve funds which are appropriated from net profits of the Corporation and its subsidiaries as proposed by the Board of Directors and subject to approval by shareholders at the annual general meetings.

##### *Investment and development fund*

This fund is set aside for use in the Corporation and its subsidiaries' expansion of their operation or of in-depth investments.

##### *Bonus and welfare fund*

This fund is set aside for the purpose of pecuniary rewarding and encouraging, common benefits and improvement of the employees' benefits, and presented as a liability on the consolidated balance sheet.

#### 3.16 Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Corporation and its subsidiaries and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable, excluding trade discount, rebate and sales return. The following specific recognition criteria must also be met before revenue is recognized:

##### *Sale of goods*

Revenue is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer, usually upon the delivery of the goods.

##### *Rendering of services*

Revenue is recognized when services are rendered and completed.

##### *Rental income*

Rental income arising from operating lease contract is recognized in the consolidated income statement on a straight-line basis over the term of the lease.

##### *Dividends and profit distribution income*

Dividend and profit distribution income are recognized when the Corporation and its subsidiaries are entitled to receive dividends or when the Corporation and its subsidiaries are entitled to receive profits from its capital contributions.

##### *Interest income*

Interest is recognized on an accrual basis based on the time and actual interest rate for each period.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.17 Taxation**

*Current income tax*

Current income tax assets and liabilities for the current and prior years are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted as at the balance sheet date.

Current income tax is charged or credited to the consolidated income statement, except when it relates to items recognized directly to equity, in which case the current income tax is also dealt with in equity.

Current income tax assets and liabilities are offset when there is a legally enforceable right for the Corporation and its subsidiaries to off-set current tax assets against current tax liabilities and when the Corporation and its subsidiaries intend to settle its current tax assets and liabilities on a net basis.

*Deferred tax*

Deferred tax is provided using the liability method on temporary differences at the balance sheet date between the tax base of assets and liabilities and their carrying amount for financial reporting purposes.

Deferred tax liabilities are recognized for all taxable temporary differences, except:

- ▶ where the deferred tax liability arises from the initial recognition of an asset or liability in a transaction which at the time of the related transaction affects neither the accounting profit nor taxable profit or loss.
- ▶ in respect of taxable temporarily differences associated with investments in subsidiaries and associates, and interests in joint ventures where timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets are recognized for all deductible temporary differences, carried forward unused tax credit and unused tax losses, to the extent that it is probable that taxable profit will be available against which deductible temporary differences, carried forward unused tax credit and unused tax losses can be utilized, except:

- ▶ where the deferred tax asset in respect of deductible temporary difference which arises from the initial recognition of an asset or liability which at the time of the related transaction, affects neither the accounting profit nor taxable profit or loss.
- ▶ in respect of deductible temporarily differences associated with investments in subsidiaries, associates, and interests in joint ventures, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Previously unrecognized deferred tax assets are re-assessed at each balance sheet date and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax assets to be recovered.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.17 Taxation (continued)**

*Deferred tax (continued)*

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled based on tax rates and tax laws that have been enacted at the consolidated balance sheet date.

Deferred tax is charged or credited to the consolidated income statement, except when it relates to items recognized directly to equity, in which case the deferred tax is also dealt with in the equity account.

Deferred tax assets and liabilities are offset when there is a legally enforceable right for the Corporation and its subsidiaries to off-set current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority on:

- ▶ either the same taxable entity; or
- ▶ when the Corporation and its subsidiaries intend either to settle current tax liabilities and assets on a net basis or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

**3.18 Earnings per share**

Basic earnings per share is calculated by dividing the profit or loss after tax attributable to the ordinary shareholders of the Corporation (after adjusting for setting up bonus and welfare funds) by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share is calculated by dividing the profit or loss after tax attributable to the ordinary shareholders of the Corporation (after adjusting for dividends of preferred shares with the right to convert) for the weighted average number of ordinary shares outstanding during the year and the weighted average number of ordinary shares that will be issued in case all potential ordinary shares with diluted impact are converted into common shares.

**3.19 Segment information**

The Corporation and its subsidiaries' principal activities are manufacture and sales of pharmaceutical products, and investment holding in activities within the pharmaceutical trading industry. In addition, these activities are mainly taking place within Vietnam. Therefore, the Corporation and its subsidiaries' risks and returns are not impacted by the products that the Corporation and its subsidiaries are manufacturing or the locations where the Corporation and its subsidiaries are trading. As a result, the Corporation's management is of the view that there is only one segment for business and geography and therefore presentation of segmental information is not required.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.20 Related parties**

Parties are considered to be related to the Corporation and its subsidiaries if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions, or where the Corporation and its subsidiaries and the other party are subject to common control or significant influence. Related parties can be enterprises or individuals, including close members of their families.

**4. SIGNIFICANT EVENTS**

In October 2025, the Corporation has subscribed additional shares in Sanofi Vietnam Joint Stock Company and increased its equity interest and voting right from 15% to 30% in this entity, and thereby obtaining significant influence over this entity. Accordingly, Sanofi Vietnam Joint Stock Company has become an associate of the Corporation.

The difference between the consideration paid and the Corporation's shares in the fair value of the associate's net assets as at acquisition date has been recognized in Share of profit of associates in the consolidated income statement (*Note 14.1*)

**5. CASH AND CASH EQUIVALENTS**

	Currency: VND	
	Ending balance	Beginning balance
Cash on hand	1,486,611,288	1,307,086,434
Cash at banks	41,939,568,648	36,909,370,985
Term deposits at banks (*)	47,900,000,000	250,850,000,000
<b>TOTAL</b>	<b>91,326,179,936</b>	<b>289,066,457,419</b>

(\*) These represent bank deposits with original term of less than 3 months and earns interest at the rates as stipulated in each deposit contract.

**6. HELD-TO-MATURITY INVESTMENTS**

Short-term held-to-maturity investments represent bank deposits with original terms of more than 6 months to 12 months and earn interest at the rates as stipulated in each deposit contract.

Long-term held-to-maturity investments represent bank deposits with original terms of 18 months and remaining terms of more than 12 months and earn interest at the rates as stipulated in each deposit contract.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**7. SHORT-TERM TRADE RECEIVABLES AND ADVANCES TO SUPPLIERS**

**7.1 Short-term trade receivables**

	Currency: VND	
	Ending balance	Beginning balance
Short-term trade receivables		
- An Vuong Pharmaceutical Company Limited	165,274,139,100	177,271,677,134
- Khun Thang Pharmaceutical Company Limited	92,080,485,250	102,299,153,275
- Other customers	1,587,073,137,112	1,305,375,347,441
<b>TOTAL</b>	<b>1,844,427,761,462</b>	<b>1,584,946,177,850</b>
Provision for doubtful short-term receivables	(54,369,298,107)	(36,598,092,829)

As at 31 December 2025, short-term trade receivables of the Corporation's subsidiaries amounting to VND 485 billion (31 December 2024: VND 663 billion) were used as collaterals for bank loans (Note 21).

**7.2 Short-term advances to suppliers**

	Currency: VND	
	Ending balance	Beginning balance
Short-term advances to suppliers		
- Y.S.P INDUSTRIES (M) SDN. BHD	3,819,076,807	-
- KALCEKS Joint Stock Company	3,428,774,400	-
- Noah Legend Co., Ltd	3,361,370,685	-
- EGIS PHARMACEUTICALS PLC	2,833,649,424	-
- Nhat Anh Pharmaceutical Co., Ltd.	-	5,890,000,000
- Other advances	10,480,580,363	25,704,615,967
<b>TOTAL</b>	<b>23,923,451,679</b>	<b>31,594,615,967</b>
Provision for short-term advances to suppliers	(216,106,684)	(278,011,205)

**7.3 Provision for doubtful short-term receivables**

	Currency: VND	
	Current year	Previous year
Beginning balance	41,053,905,410	29,981,140,924
Add: Provision made during the year	36,337,748,436	18,575,002,793
Less: Reversal during the year	(18,131,131,695)	(7,502,238,307)
Ending balance	59,260,522,151	41,053,905,410

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**8. OTHER SHORT-TERM RECEIVABLES**

Currency: VND

	<i>Ending balance</i>		<i>Beginning balance</i>	
	<i>Balance</i>	<i>Provision</i>	<i>Balance</i>	<i>Provision</i>
Dividend receivables	-	-	6,936,127,000	-
Interest receivables	7,058,730,797	-	7,276,635,876	-
Advances to employees	1,636,003,372	-	4,602,854,367	-
Receivables for trust import activities	1,659,798,876	-	7,015,892,573	-
Receivables from sales support	42,671,139,499	-	29,164,537,400	-
Deposit, mortgages or collaterals	5,158,397,051	-	4,326,420,247	-
Compensation for disposal of obsolete inventory	12,292,638,682	-	-	-
Others	36,183,891,525	(4,675,117,360)	10,877,095,807	(4,618,407,897)
<b>TOTAL</b>	<b>106,660,599,802</b>	<b>(4,675,117,360)</b>	<b>70,199,563,270</b>	<b>(4,618,407,897)</b>

**9. BAD DEBTS**

Currency: VND

	<i>Ending balance</i>		<i>Beginning balance</i>	
	<i>Cost</i>	<i>Recoverable amount</i>	<i>Cost</i>	<i>Recoverable amount</i>
Mi Nguyen Pharmaceutical Trading Company Limited	20,441,836,178	-	19,954,092,956	5,278,990,203
Asia Medical Food Company Limited	18,008,018,716	11,383,706,626	-	-
Gravitas Joint Stock Company	11,312,827,360	8,425,394,609	-	-
Kim Chau Pharmaceutical Co., Ltd.	4,086,849,776	-	4,086,849,776	-
Hoang An Medical Equipment Joint Stock Company	3,124,998,992	-	3,186,903,513	-
Other overdue receivables	33,112,120,617	11,017,028,253	28,408,171,839	9,303,122,471
<b>TOTAL</b>	<b>90,086,651,639</b>	<b>30,826,129,488</b>	<b>55,636,018,084</b>	<b>14,582,112,674</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**10. INVENTORIES**

Currency: VND

	Ending balance		Beginning balance	
	Cost	Provision	Cost	Provision
Goods in transit	128,938,983,878	-	117,684,774,764	-
Raw materials	13,353,403,932	(816,086,623)	12,711,938,105	(22,370,242)
Work-in-process	1,822,465,906	-	4,006,801,085	-
Finished goods	9,538,878,558	(32,863,970)	5,463,705,329	(12,311,993)
Merchandise	1,861,811,786,639	(11,855,688,846)	1,522,950,128,670	(29,546,041,060)
Goods on consignment	376,441,044	-	-	-
<b>TOTAL</b>	<b>2,015,841,959,957</b>	<b>(12,704,639,439)</b>	<b>1,662,817,347,953</b>	<b>(29,580,723,295)</b>

As at 31 December 2025, certain inventories amounting to VND 387 billion (31 December 2024: VND 740 billion) were used as collaterals for bank loans (Note 21).

**Movements of provision for obsolete inventories**

Currency: VND

	Current year	Previous year
Beginning balance	29,580,723,295	61,795,596,759
Add: Provision made during the year	23,183,400,857	9,093,610,325
Less: Utilization during the year	(37,280,135,164)	(1,330,926,437)
Less: Reversal during the year	(2,779,349,549)	(39,977,557,352)
Ending balance	<u>12,704,639,439</u>	<u>29,580,723,295</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**11. TANGIBLE FIXED ASSETS**

	Buildings and structures	Machinery and equipment	Means of transportation	Office equipment	Others	Currency: VND Total
<b>Cost:</b>						
Beginning balance	315,020,865,028	122,175,387,616	71,822,992,988	9,151,209,673	335,696,431	518,506,151,736
- Transfer from construction in progress	6,940,981,286	820,000,000	-	-	-	7,760,981,286
- New purchases	1,788,918,133	2,473,321,370	601,608,889	694,511,364	-	5,558,359,756
- Disposal	-	(701,339,100)	(4,262,551,598)	(377,644,732)	-	(5,341,535,430)
- Decrease due to transfer of a subsidiary	(5,825,210,135)	(4,431,765,720)	(1,737,682,747)	-	(277,888,968)	(12,272,547,570)
Ending balance	317,925,554,312	120,335,604,166	66,424,367,532	9,468,076,305	57,807,463	514,211,409,778
<i>In which:</i>						
Fully depreciated	89,004,652,079	55,448,303,049	34,383,266,211	7,035,344,956	57,807,463	185,929,373,758
<b>Accumulated depreciation:</b>						
Beginning balance	186,918,143,068	96,943,228,520	52,022,895,166	7,811,750,305	335,696,431	344,031,713,490
- Depreciation for the year	10,357,836,162	8,630,156,085	4,157,393,327	630,800,850	-	23,776,186,424
- Disposal	-	(651,660,970)	(4,262,551,598)	(377,644,732)	-	(5,291,857,300)
- Decrease due to transfer of a subsidiary	(5,825,210,135)	(4,431,765,720)	(1,737,682,747)	-	(277,888,968)	(12,272,547,570)
- Other increase	51,659,382	-	-	-	-	51,659,382
Ending balance	191,502,428,477	100,489,957,915	50,180,054,148	8,064,906,423	57,807,463	350,295,154,426
<b>Net carrying amount:</b>						
Beginning balance	128,102,721,960	25,232,159,096	19,800,097,822	1,339,459,368	-	174,474,438,246
Ending balance	126,423,125,835	19,845,646,251	16,244,313,384	1,403,169,882	-	163,916,255,352

As at 31 December 2025, certain tangible fixed assets with the carrying value of VND 4.16 billion (31 December 2024: VND 4.3 billion) were pledged as security for bank loans (Note 21).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**12. INTANGIBLE FIXED ASSETS**

	Currency: VND		
	<i>Land use rights</i>	<i>Computer software</i>	<i>Total</i>
<b>Cost:</b>			
Beginning balance	123,420,668,307	6,098,204,838	129,518,873,145
- Decrease due to transfer of a subsidiary	<u>(467,777,662)</u>	<u>(164,025,638)</u>	<u>(631,803,300)</u>
Ending balance	<u>122,952,890,645</u>	<u>5,934,179,200</u>	<u>128,887,069,845</u>
<i>In which:</i>			
<i>Fully amortized</i>	563,897,536	2,871,213,200	3,435,110,736
<b>Accumulated amortization:</b>			
Beginning balance	18,071,926,564	4,746,882,994	22,818,809,558
- Amortization for the year	2,539,673,028	428,343,204	2,968,016,232
- Decrease due to transfer of a subsidiary	<u>(467,777,662)</u>	<u>(164,025,638)</u>	<u>(631,803,300)</u>
Ending balance	<u>20,143,821,930</u>	<u>5,011,200,560</u>	<u>25,155,022,490</u>
<b>Net carrying amount:</b>			
Beginning balance	<u>105,348,741,743</u>	<u>1,351,321,844</u>	<u>106,700,063,587</u>
Ending balance	<u>102,809,068,715</u>	<u>922,978,640</u>	<u>103,732,047,355</u>

As at 31 December 2025, the Corporation's subsidiary used land use right at 132A Nguyen Van Cu street, Tan An ward, Can Tho city as collaterals for bank loans (Note 21).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

13. INVESTMENT PROPERTIES

Currency: VND

*Buildings & structures*

**Cost:**

Beginning balance	45,821,328,558
Ending balance	45,821,328,558

*In which:*

*Fully depreciated* -

**Accumulated depreciation:**

Beginning balance	10,061,852,809
- Depreciation for the year	1,031,828,940
- Other decrease	(51,659,382)
Ending balance	11,042,022,367

**Net carrying amount:**

Beginning balance	35,759,475,749
Ending balance	34,779,306,191

The Corporation's investment properties mainly consist of office spaces at the Commercial Office and High-class Apartment Complex of PVV – Vinapharm Project, which are held under operating lease.

The Corporation has not been able to obtain necessary information to determine the fair value of these investment properties for disclosure purpose.

14. LONG-TERM INVESTMENTS

Currency: VND

	<i>Ending balance</i>	<i>Beginning balance</i>
Investments in associates (Note 14.1)	2,032,899,478,459	987,874,650,144
Investments in other entities (Note 14.2)	697,823,455,837	870,823,455,837
Provision for long-term financial investments	(140,200,239,456)	(120,164,587,830)
Long-term held-to-maturity investments (Note 6)	12,000,000,000	-
<b>TOTAL</b>	<b>2,602,522,694,840</b>	<b>1,738,533,518,151</b>

**Movements of provision for long-term investments:**

Currency: VND

	<i>Current year</i>	<i>Previous year</i>
Beginning balance	120,164,587,830	123,486,516,430
Add: Provision made during the year	32,525,086,115	19,251,811,850
Less: Reversal during the year	(12,489,434,489)	(22,573,740,450)
Ending balance	140,200,239,456	120,164,587,830

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**14. LONG-TERM INVESTMENTS (continued)**

**14.1 Investments in associates**

Details of the Corporation and its subsidiaries' associates are as follows:

Name	Location	Principal activities	Beginning balance			Ending balance		
			Capital contribution	Voting rights	Ownership and interest	Capital contribution	Voting rights	Ownership and interest
Vietnam Medical Products Import - Export Joint Stock Company	138 Giang Vo, Giang Vo ward, Hanoi	Trading, importing-exporting pharmaceutical products (raw materials and finished goods) and chemicals	41.15%	41.15%	41.15%	41.15%	41.15%	41.15%
Sanofi Vietnam Joint Stock Company	Lot 1-8-2, D8 road, High tech zone, Tang Nhon Phu ward, Ho Chi Minh city	Manufacturing, researching and developing pharmaceutical, cosmetic and supplementary products	30.00%	30.00%	30.00%	-	-	-
Sanofi-Synthelabo Vietnam Pharmaceutical Shareholding Company	3A-3B Ton Duc Thang street, Sai Gon ward, Ho Chi Minh city	Manufacturing drugs, pharmaceutical products and chemicals	30.00%	30.00%	30.00%	30.00%	30.00%	30.00%
Central Pharmaceutical Joint Stock Company No. 25	448B Nguyen Tat Thanh, Xom Chieu ward, Ho Chi Minh city	Manufacturing drugs, pharmaceutical products and chemicals	28.43%	28.43%	28.43%	28.43%	28.43%	28.43%
Danapha Pharmaceutical Joint Stock Company	253 Dung Si Thanh Khe, Thanh Khe ward, Da Nang city	Manufacturing drugs, pharmaceutical products and chemicals	26.45%	26.45%	26.45%	26.45%	26.45%	26.45%
Davina Pharmaceutical Joint Stock Company	253 Dung Si Thanh Khe, Thanh Khe ward, Da Nang city	Manufacturing drugs, pharmaceutical products and chemicals	25.00%	25.00%	25.00%	25.00%	25.00%	25.00%
Central Pharmaceutical Joint Stock Company No. 3	16 Le Dai Hanh, Hong Bang ward, Hai Phong city	Producing drugs, pharmaceutical chemistry and materials	22.07%	22.07%	22.07%	22.07%	22.07%	22.07%
Imexpharm Corporation	No 4, 30/4 street, Cao Lanh ward, Dong Thap province	Manufacturing and trading, importing - exporting pharmaceutical products, medical machineries and equipment, pharmaceutical packages	22.04%	22.04%	22.04%	22.04%	22.04%	22.04%
Alfresa Codupha Healthcare Vietnam Co., Ltd.	262L Le Van Sy, Nhieu Loc ward, Ho Chi Minh city	Wholesale of pharmaceutical chemistry and materials	30.00%	30.00%	19.97%	30.00%	30.00%	19.97%

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**14. LONG-TERM INVESTMENTS** (continued)

**14.1 Investments in associates** (continued)

	Ending balance		Beginning balance		Currency: VND
	Investments accounted for using the equity method	Fair value	Investments accounted for using the equity method	Fair value	
Vietnam Medical Products Import - Export Joint Stock Company	17,259,025,266	(*)	17,076,577,847	(*)	
Sanofi Joint Stock Company (**)	1,070,346,307,643	(*)	-	-	
Sanofi-Synthelabo Vietnam Pharmaceutical Shareholding Company	28,422,881,893	(*)	124,222,288,290	(*)	
Central Pharmaceutical Joint Stock Company No.25 (i)	44,757,744,543	37,800,000,000	44,113,745,307	38,556,000,000	
Danapha Pharmaceutical Joint Stock Company (i)	224,981,242,123	202,696,912,200	202,300,485,426	171,683,177,000	
Davina Pharmaceutical Joint Stock Company	-	(*)	-	(*)	
Central Pharmaceutical Joint Stock Company No.3 (i)	134,757,629,509	250,593,393,600	114,542,763,511	276,696,872,100	
Imexpharm Corporation (i)	508,437,675,174	1,782,322,080,000	481,234,715,585	1,595,602,624,000	
Alfresa Codupha Healthcare Vietnam Co., Ltd.	3,936,972,308	(*)	4,384,074,178	(*)	
<b>TOTAL</b>	<b>2,032,899,478,459</b>		<b>987,874,650,144</b>		

(i) The fair value of these investments was determined by reference to the closing prices (either at the reporting date or the transaction date closest to the reporting date) of the shares of the companies listed on the stock exchanges.

(\*) The Corporation has not been able to determine the fair value of these investments for disclosure purpose in the consolidated financial statements because market prices of these shares are not available. The fair value of these financial investments may differ from their carrying amounts.

(\*\*) See details in Note 4.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**14. LONG-TERM INVESTMENTS (continued)**

**14.1 Investments in associates (continued)**

Currency: VND

No.	Company name	Beginning balance	Reclassification from Investment in other entities	Share of profit/(loss) during the year	Increase in cost of investment	Gain from bargain purchase (**)	Dividends received	Other decrease (*)	Ending balance
1.	Vietnam Medical Products Import- Export Joint Stock Company	17,076,577,847	-	1,667,447,419	-	-	(1,485,000,000)	-	17,259,025,266
2.	Sanofi Vietnam Joint Stock Company (**)	-	173,000,000,000	15,961,917,282	496,794,524,073	384,589,866,288	-	-	1,070,346,307,643
3.	Sanofi-Synthelabo Vietnam Pharmaceutical Shareholding Company (*)	124,222,288,290	-	199,313,603	-	-	(74,364,836,225)	(21,633,883,775)	28,422,881,893
4.	No.25 Central Pharmaceutical Joint Stock Company	44,113,745,307	-	643,999,236	-	-	-	-	44,757,744,543
5.	Danapha Pharmaceutical Joint Stock Company	202,300,485,426	-	22,680,756,697	-	-	-	-	224,981,242,123
6.	Davina Pharmaceutical Joint Stock Company	-	-	-	-	-	-	-	-
7.	Central Pharmaceutical Joint Stock Company No.3	114,542,763,511	-	34,453,126,998	-	-	(14,238,261,000)	-	134,757,629,509
8.	Imexpharm Corporation	481,234,715,585	-	44,177,455,589	-	-	(16,974,496,000)	-	508,437,675,174
9.	Alfresa Codupha Healthcare Vietnam Co., Ltd.	4,384,074,178	-	(447,101,870)	-	-	-	-	3,936,972,308
	<b>TOTAL</b>	<b>987,874,650,144</b>	<b>173,000,000,000</b>	<b>119,336,914,954</b>	<b>496,794,524,073</b>	<b>384,589,866,288</b>	<b>(107,062,593,225)</b>	<b>(21,633,883,775)</b>	<b>2,032,899,478,459</b>

(\*) During the year, the Corporation recognized a deduction in the cost of investment in Sanofi-Synthelabo Vietnam Pharmaceutical Joint Stock Company due to the receipt of dividends declared from accumulated profit arising before the date when the Corporation was transformed to a joint stock company. As at the date of these consolidated financial statements, the Corporation is co-ordinating with this associate to complete the dissolution procedures and to close the operations of this company according to prevailing regulations.

(\*\*) See details in Note 4.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

14. LONG-TERM INVESTMENTS (continued)

14.2 Investments in other entities

Currency: VND

	Ending balance			Beginning balance				
	Ownership rate	Cost	Provision	Fair value	Ownership rate	Cost	Provision	Fair value
Mekophar Chemical Pharmaceutical Joint Stock Company (i)	18.40%	200,503,651,417	(81,918,274,717)	118,585,376,700	18.40%	200,503,651,417	(65,854,916,917)	134,648,734,500
Sanofi Vietnam Joint Stock Company (iii)	-	-	-	-	15.00%	173,000,000,000	-	(*)
Pharmaceutical Packaging Joint Stock Company	15.00%	11,370,153,435	-	(*)	15.00%	11,370,153,435	-	(*)
Vidipha Central Pharmaceutical Joint Stock Company (i)	14.36%	75,628,326,988	-	184,308,166,000	14.36%	75,628,326,988	-	117,575,899,000
OPC Pharmaceutical Joint Stock Company (i)	13.40%	139,411,862,876	-	206,063,664,000	13.40%	139,411,862,876	-	214,649,650,000
Mediplantex Central Pharmaceutical Joint Stock Company (i)	11.50%	29,455,746,106	-	33,546,250,000	11.50%	29,455,746,106	-	37,115,000,000
Vimedimex Medicine and Pharmacy Joint Stock Company (i)	10.23%	46,022,915,860	(19,955,671,360)	26,067,244,500	10.23%	46,022,915,860	(19,955,671,360)	26,067,244,500
National Phytopharma Joint Stock Company	9.90%	37,739,465,978	-	(*)	9.90%	37,739,465,978	-	(*)
Medipharco Pharmaceutical Joint Stock Company (i)	9.10%	9,231,455,589	-	9,499,014,000	9.10%	9,231,455,589	(750,193,089)	8,481,262,500
Vietnam Pharmaceutical Chemical Joint Stock Company	7.76%	5,107,203,820	-	(*)	7.76%	5,107,203,820	-	(*)
Central Pharmaceutical Joint Stock Company No. 2 (i)	6.78%	11,861,708,288	(7,116,720,303)	4,744,987,985	6.78%	11,861,708,288	(4,807,128,288)	7,054,580,000
Yen Bai Pharmaceutical Joint Stock Company	5.73%	3,466,940,866	-	(*)	5.73%	3,466,940,866	-	(*)
Pharbaco - Central Pharmaceutical Joint Stock Company No.1 (i)	5.18%	69,305,080,876	(31,209,573,076)	38,095,507,800	5.18%	69,305,080,876	(28,796,678,176)	40,508,402,700
CPC1 Hanoi Pharmaceutical Joint Stock Company (i)	10.75%	27,776,985,675	-	618,133,178,800	10.75%	27,776,985,675	-	365,333,242,000
Tuyen Quang Pharmaceutical and Trading Services Joint Stock Company	0.81%	670,269,026	-	(*)	0.81%	670,269,026	-	(*)
Ha Tinh Pharmaceutical Joint Stock Company (i)	0.65%	971,029,662	-	2,545,537,500	0.65%	971,029,662	-	1,996,500,000
TV. Pharm Pharmaceutical Joint Stock Company	0.10%	300,659,375	-	(*)	0.10%	300,659,375	-	(*)
Indochina Urban Development Joint Stock Company (ii)	2.53%	6,017,000,000	-	(*)	2.53%	6,017,000,000	-	(*)
Kingdom Indochina Joint Stock Company (ii)	2.44%	22,983,000,000	-	(*)	2.44%	22,983,000,000	-	(*)
TOTAL		697,823,455,837	(140,200,239,456)			870,823,455,837	(120,164,587,830)	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**14. LONG-TERM INVESTMENTS** (continued)

**14.2 Investments in other entities** (continued)

- (i) The fair value of these investments was determined by reference to the share's closing prices (at the ending date or the transaction date closest to the reporting date) of the companies listed on stock exchanges.
- (ii) As at 31 December 2025, a subsidiary of the Corporation has pledged all shares in Indochina Urban Development Joint Stock Company and Kingdom Indochina Joint Stock Company as securities for its loans (*Note 21*).
- (iii) See details in Note 4.
- (\*) The Corporation has not been able to determine the fair value of these investments for disclosure purpose in the consolidated financial statements because market prices of these shares are not available. The fair value of these financial investments may differ from their carrying amounts.

**15. LONG-TERM PREPAID EXPENSES**

	Currency: VND	
	<i>Ending balance</i>	<i>Beginning balance</i>
Prepaid land rental	23,912,740,583	24,933,986,855
Tools and supplies	1,477,625,562	1,690,891,003
Other long-term prepaid expenses	4,302,810,601	4,085,605,171
<b>TOTAL</b>	<b>29,693,176,746</b>	<b>30,710,483,029</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**16. SHORT-TERM TRADE PAYABLES AND ADVANCES FROM CUSTOMERS**

**16.1 Short-term trade payables**

Currency: VND

	Ending balance		Beginning balance	
	Amount	Payable amount	Amount	Payable amount
Short-term trade payables to suppliers				
- Hisamitsu Vietnam Pharmaceutical Co., Ltd.	252,765,103,748	252,765,103,748	228,034,625,325	228,034,625,325
- Celltrion Inc.	195,096,097,291	195,096,097,291	-	-
- Novapri Lifescience Private Limited	162,930,176,208	162,930,176,208	104,218,476,026	104,218,476,026
- Hyphens Pharma Co., Ltd.	86,327,651,821	86,327,651,821	142,810,055,819	142,810,055,819
- Other suppliers	1,143,426,967,463	1,143,426,967,463	1,072,798,244,143	1,072,798,244,143
Short-term payables to related parties (Note 31)	10,087,360,079	10,087,360,079	8,019,810,193	8,019,810,193
<b>TOTAL</b>	<b>1,850,633,356,610</b>	<b>1,850,633,356,610</b>	<b>1,555,881,211,506</b>	<b>1,555,881,211,506</b>

**16.2 Short-term advances from customers**

Currency: VND

	Ending balance	Beginning balance
Advances from customers		
- Phi Long Medical Equipment and Pharmaceuticals Jsc	7,040,270,532	-
- Truong Ton Trade & Pharmaceutical Co., Ltd	5,052,302,300	3,378,237,903
- Ngoc My International Trading Co., Ltd	4,468,351,745	-
- Other customers	22,858,650,114	19,232,042,706
<b>TOTAL</b>	<b>39,419,574,691</b>	<b>22,610,280,609</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

# 17. STATUTORY OBLIGATIONS

Currency: VND

	Beginning balance		Movement during the year		Ending balance	
	Amount receivables	Amount payables	Amount payable in the year	Amount deducted in the year	Amount receivables	Amount payables
Domestic value-added tax	(138,528,103)	324,596,144	314,979,058,825	(311,402,162,729)	(71,889,585)	162,825,549
Import value-added tax	(860,208,119)	5,386,196	113,982,578,554	-	(834,393,725)	-
Import duties	(65,556,585)	3,137,587	10,663,004,627	-	(45,119,844)	-
Corporate income tax	(1,269,350,171)	32,512,853,666	31,879,281,718	-	(1,270,157,785)	4,067,765,190
Personal income tax	(90,506,868)	490,182,033	8,693,948,952	(54,412,371)	(21,758)	667,339,918
Land use tax	-	2,043,978,378	16,677,631,912	-	(5,075,957,793)	1,655,223,973
Other fees	(13,031,416)	16,896,282,797	1,014,423,840	-	-	16,971,375,782
<b>TOTAL</b>	<b>(2,437,181,262)</b>	<b>52,276,416,801</b>	<b>497,889,928,428</b>	<b>(311,456,575,100)</b>	<b>(7,297,540,490)</b>	<b>23,524,530,412</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**18. SHORT-TERM ACCRUED EXPENSES**

	Currency: VND	
	Ending balance	Beginning balance
Accrued bonus	4,500,000,000	4,479,750,000
Interest payables	2,250,308,215	952,684,597
Other accruals	5,483,727,614	5,037,205,055
<b>TOTAL</b>	<b>12,234,035,829</b>	<b>10,469,639,652</b>

**19. OTHER SHORT-TERM PAYABLES**

	Currency: VND	
	Ending balance	Beginning balance
Payables related to trust import activities (i)	5,638,382,776	11,909,858,335
Dividend payables	2,693,197,477	360,688,965
Deposits and collaterals	1,621,541,128	479,001,586
Other payables	7,468,392,827	8,343,527,768
<b>TOTAL</b>	<b>17,421,514,208</b>	<b>21,093,076,654</b>

(i) This is payables to suppliers from trust import shipments completed during the year.

**20. BONUS AND WELFARE FUNDS**

	Currency: VND	
	Current year	Previous year
Beginning balance	15,147,021,633	9,353,401,594
Appropriation for the year (Note 22.1)	14,894,453,292	22,146,639,232
Other decrease	-	(1,786,409)
Utilization during the year	(8,166,105,961)	(16,351,232,784)
Ending balance	21,875,368,964	15,147,021,633

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

21. LOANS

Currency: VND

	Beginning balance		Movement during the year		Ending balance	
	Balance	Payable amount	Increase	Decrease	Balance	Payable amount
<b>Short-term loans</b>						
Loan from banks (Note 21.1)	1,195,578,041,740	1,195,578,041,740	4,614,968,333,105	(4,232,412,994,350)	1,578,133,380,495	1,578,133,380,495
Loan from individuals (Note 21.2)	11,538,000,000	11,538,000,000	3,395,000,000	(5,704,000,000)	9,229,000,000	9,229,000,000
Current portion of long-term loans from banks (Note 21.3)	398,588,612	398,588,612	398,588,612	(398,588,612)	398,588,612	398,588,612
<b>TOTAL</b>	<b>1,207,514,630,352</b>	<b>1,207,514,630,352</b>	<b>4,618,761,921,717</b>	<b>(4,238,515,582,962)</b>	<b>1,587,760,969,107</b>	<b>1,587,760,969,107</b>
<b>Long-term loans</b>						
Loans from banks (Note 21.3)	1,195,765,848	1,195,765,848	-	(398,588,612)	797,177,236	797,177,236
Loans from others (Note 21.3)	29,000,000,000	29,000,000,000	-	-	29,000,000,000	29,000,000,000
<b>TOTAL</b>	<b>30,195,765,848</b>	<b>30,195,765,848</b>	<b>-</b>	<b>(398,588,612)</b>	<b>29,797,177,236</b>	<b>29,797,177,236</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**21. LOANS** (continued)

**21.1 Short-term loans from bank**

<i>Lenders</i>	<i>Ending balance (VND)</i>	<i>Principal and interest payment term</i>	<i>Interest rate (per annum)</i>	<i>Description of collateral</i>
Vietnam Joint Stock Commercial Bank for Industry and Trade - Ho Chi Minh City Branch	449,152,811,079	Term loan of 6 months. Last principal is due on 25 June 2026. Interest is payable monthly.	5.2% - 7.3%	Debt collection rights arising from contracts signed between Codupha Central Pharmaceutical Joint Stock Company and its customers amounting to VND 275 billion; a part of inventories with the average value of VND 210 billion.
Military Commercial Joint Stock Bank - Northern Sai Gon Branch	192,150,201,035	Term loan of 6 months. Last principal is due on 30 June 2026. Interest is payable monthly.	5.2% - 7.0%	The land use rights located at 132A Nguyen Van Cu street, Tan An ward, Can Tho City of Codupha Central Pharmaceutical Joint Stock Company
Vietnam International Commercial Joint Stock Bank	172,270,471,681	Term loan of 6 months. Last principal is due on 31 May 2026. Interest is payable monthly.	5.2% - 7.8%	Inventories and trade receivables of Codupha Central Pharmaceutical Joint Stock Company amounting to at least VND 300 billion.
Vietnam Maritime Commercial Joint Stock Bank - Transaction Center Branch	147,496,530,252	Term loan of 4-5 months. Last principal is due on 1 June 2026. Interest is payable monthly.	4.1% - 5.7%	Unsecured.
Joint Stock Commercial Bank for Investment and Development of Vietnam - Hoan Kiem Branch	109,585,026,864	Term loan of 5.5-6 months. Last principal is due on 22 May 2026. Interest is payable monthly.	4.2% - 4.8%	Unsecured.
Joint Stock Commercial Bank for Foreign Trade of Vietnam - Transaction Center Branch	108,168,935,469	Term loan of 3-6 months. Last principal is due on 18 June 2026. Interest is payable monthly.	4.3% - 6.8%	Unsecured.
Others	399,309,404,115	Last principal is due on 14 November 2026. Interest is payable monthly.	4.2% - 6.7%	Certain assets which are inventories and debt collection rights arising from contracts signed between the Corporation' subsidiaries or circulating debt collection rights.

**TOTAL**

**1,578,133,380,495**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**21. LOANS (continued)**

**21.2 Short-term loans from individuals**

<i>Lenders</i>	<i>Ending balance (VND)</i>	<i>Principal and interest payment term</i>	<i>Interest rate (per annum)</i>	<i>Description of collateral</i>
Loans from employees	9,129,000,000	Principal is repayable on demand. Loan interest is payable quarterly.	5.7%	Unsecured.
Loans from individuals	100,000,000	Principal is repayable on demand. Loan interest is payable monthly.	12%	Unsecured.
<b>TOTAL</b>	<b>9,229,000,000</b>			

**21.3 Long-term loans**

<i>Lenders</i>	<i>Ending balance (VND)</i>	<i>Principal and interest payment term</i>	<i>Interest rate (per annum)</i>	<i>Description of collateral</i>
Vietnam Joint Stock Commercial Bank for Industry and Trade – Da Nang Branch	1,195,765,848	Final drawdown will mature on 1 March 2029. Interest is payable monthly.	12.5%	Certain buildings and structures, machineries and equipments of Central Pharmaceutical Joint Stock Company No.3.
<i>In which:</i>				
<i>Current portion of long-term loans</i>	398,588,612			
<i>Long-term loans</i>	797,177,236			
Hoa Lam Investment and Development Joint Stock Company	29,000,000,000	Final drawdown will mature on 31 December 2027.	0%	Shares owned by Codupha Central Pharmaceutical Joint Stock Company in Indochina Urban Development Joint Stock Company Kingdom Indochina Joint Stock Company
<i>In which:</i>				
<i>Current portion of long-term loans</i>	-			
<i>Long-term loans</i>	29,000,000,000			
<b>TOTAL</b>	<b>30,195,765,848</b>			
<i>In which:</i>				
<i>Current portion of long-term loans</i>	398,588,612			
<i>Long-term loans</i>	29,797,177,236			

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**22. OWNERS' EQUITY**

**22.1 Increase and decrease in owners' equity**

Currency: VND									
	Issued share capital	Other capital	Asset revaluation reserve	Foreign exchange differences reserve	Investment and development fund	Other funds belonging to owners' equity	Undistributed earnings	Non-controlling interests	Total
Previous year									
Beginning balance	2,370,000,000,000	57,739,257,171	(388,400,444,386)	(5,896,797,638)	349,450,358,079	982,699,119	616,315,629,334	236,695,504,100	3,236,886,205,779
- Net profit for the year	-	-	-	-	-	-	420,814,703,639	47,280,423,116	468,095,126,755
- Cash dividends	-	-	-	-	-	-	(165,899,949,732)	(20,017,885,268)	(185,917,835,000)
- Appropriation for investment and development fund	-	-	-	-	67,333,390,287	-	(67,333,390,287)	-	-
- Appropriation for bonus and welfare fund	-	-	-	-	-	-	(9,913,744,122)	(5,232,895,110)	(15,146,639,232)
- Provisional appropriation for bonus and welfare fund from the profit of 2024	-	-	-	-	-	-	(4,636,870,000)	(2,363,130,000)	(7,000,000,000)
- Other increases/ (decrease)	-	(142,246,763)	-	5,887,786,776	(486,165,557)	24,208	3,516,018,995	4,243,662,919	13,019,080,578
Ending balance	2,370,000,000,000	57,597,010,408	(388,400,444,386)	(9,010,862)	416,297,582,809	982,723,327	792,862,397,827	260,605,679,757	3,509,935,938,880

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**22. OWNERS' EQUITY (continued)**

**22.1 Increase and decrease in owners' equity (continued)**

Currency: VND

Current year	Issued share capital	Other capital	Asset revaluation reserve	Foreign exchange differences reserve	Investment and development fund	Other funds belonging to owners' equity	Undistributed earnings	Non-controlling interests	Total
Beginning balance	2,370,000,000,000	57,597,010,408	(388,400,444,386)	(9,010,862)	416,297,582,809	982,723,327	792,862,397,827	260,605,679,757	3,509,935,938,880
- Net profit for the year	-	-	-	-	-	-	738,599,083,819	52,216,842,614	790,815,926,433
- Cash dividends (*)	-	-	-	-	-	-	(237,000,000,000)	(17,186,230,000)	(254,186,230,000)
- Appropriation for investment and development fund (*)	-	-	-	-	1,403,475,776	-	(1,403,475,776)	-	-
- Appropriation for bonus and welfare fund (*)	-	-	-	-	-	-	(10,832,376,367)	(4,062,076,925)	(14,894,453,292)
- Adjustment due to pre-equitisation dividends from an associate	-	-	21,633,883,775	-	-	-	(21,633,883,775)	-	-
- Other increases/ (decrease)	-	-	-	9,010,862	-	-	(9,010,862)	-	-
Ending balance	2,370,000,000,000	57,597,010,408	(366,766,560,611)	-	417,701,058,585	982,723,327	1,260,582,734,866	291,574,215,446	4,031,671,182,021

(\*) The Corporation and its subsidiaries declared dividends and appropriated undistributed earnings of 2024 to investment and development fund as well as bonus and welfare fund in accordance with the Resolution of the General Meetings of Shareholders of the Corporation and its subsidiaries.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**22. OWNERS' EQUITY (continued)**

**22.2 Details of owners' shares capital**

*Unit: Shares*

	<i>Ending balance</i>			<i>Beginning balance</i>		
	<i>Total</i>	<i>Ordinary shares</i>	<i>Preferred shares</i>	<i>Total</i>	<i>Ordinary shares</i>	<i>Preferred shares</i>
State capital (*)	154,050,000	154,050,000	-	154,050,000	154,050,000	-
Other shareholders	82,950,000	82,950,000	-	82,950,000	82,950,000	-
<b>TOTAL</b>	<b>237,000,000</b>	<b>237,000,000</b>	<b>-</b>	<b>237,000,000</b>	<b>237,000,000</b>	<b>-</b>

(\*) In accordance with Decision No. 471/TTg – DMDN dated 27 May 2023 of the Prime Minister, the right to represent the State capital ownership in Vietnam Pharmaceutical Corporation was transferred from the Ministry of Health to State Capital and Investment Corporation (SCIC).

**22.3 Capital transactions with owners and distribution of dividends, profits**

*Currency: VND*

	<i>Current year</i>	<i>Previous year</i>
<b>Contributed capital</b>		
Beginning balance	2,370,000,000,000	2,370,000,000,000
Increase	-	-
Ending balance	<u>2,370,000,000,000</u>	<u>2,370,000,000,000</u>
<b>Dividends declared</b>		
Dividends for 2024	237,000,000,000	-
Dividends for 2023	-	165,900,000,000
<b>Dividends paid</b>		
Dividends for 2024	237,000,000,000	-
Dividends for 2023	-	165,900,000,000
Dividends for 2021	-	24,360,000
Dividends for 2020	-	28,403,000
Dividends for 2019	-	11,160,000
Dividends for 2018	-	7,800,000

**22.4 Shares**

*Unit: Shares*

	<i>Ending balance</i>	<i>Beginning balance</i>
<b>Authorized share capital</b>	<b>237,000,000</b>	<b>237,000,000</b>
<b>Issued shares</b>		
Ordinary shares	237,000,000	237,000,000
Preferred shares	-	-
<b>Shares in circulation</b>		
Ordinary shares	237,000,000	237,000,000
Preferred shares	-	-

The par value of share in circulation during the year is VND 10,000/share (31 December 2024: VND 10,000/share).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**23. OFF BALANCE SHEET ITEMS**

ITEM	Ending balance	Beginning balance
1. Foreign Currency:		
- US Dollar (USD)	12,965	14,627
- Euro (EUR)	575	1,320
- Baht Thailand (THB)	-	62,602
- Kip Laos (LAK)	-	990,664
- Hungarian Forint (HUF)	20,000	20,000
- Russian Ruble (RUB)	662,000	662,000
2. Goods held for third parties (unit)		
- Pharmaceutical products		
Box	1,207,802	1,095,880
Tube	124,567	27,877
Ampoule	118,509	1,589
Bottle	91,714	26,278
Bag	50,310	57,960
Tablet	320,922	80,682
Jar	3,115	11,523
Others	51,889	29,438
- Medical equipments		
Unit	222,500	-
3. Import goods held in trust for third parties (VND)	-	77,976,162,747

**24. REVENUES**

**24.1 Revenue from sale of goods and rendering of services**

	Currency: VND	
	Current year	Previous year
<b>Gross revenue</b>	<b>5,674,802,482,975</b>	<b>5,529,361,265,970</b>
<i>In which:</i>		
Revenue from sale of finished goods and merchandises	5,582,384,385,423	5,431,578,003,446
Revenue from rendering of services	92,418,097,552	79,126,788,262
Sale of investment properties	-	18,656,474,262
<b>Deductions</b>	<b>(29,208,672,409)</b>	<b>(7,559,820,824)</b>
Sales returns	(27,514,244,214)	(5,708,190,014)
Sales discount	(1,694,428,195)	(812,084,413)
Sale allowances	-	(1,039,546,397)
<b>Net revenue</b>	<b>5,645,593,810,566</b>	<b>5,521,801,445,146</b>
<i>In which:</i>		
Net revenue from sale of finished goods and merchandises	5,553,175,713,014	5,424,018,182,622
Net revenue from rendering of services	92,418,097,552	79,126,788,262
Sale of investment properties	-	18,656,474,262
<i>In which:</i>		
Sales to others	5,645,352,952,512	5,518,940,790,476
Sales to related parties (Note 31)	240,858,054	2,860,654,670

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**24. REVENUES (continued)**

**24.2 Finance income**

	Currency: VND	
	Current year	Previous year
Dividend income	147,130,720,686	162,671,888,300
Deposit interest income	50,625,136,060	49,660,741,160
Foreign exchange gains	40,267,558,397	28,559,858,158
Interest income on credit sale	2,399,636,562	3,500,767,640
Others	22,426,417,497	13,790,570,062
<b>TOTAL</b>	<b>262,849,469,202</b>	<b>258,183,825,320</b>

**25. COST OF GOODS SOLD AND SERVICES RENDERED**

	Currency: VND	
	Current year	Previous year
Cost of finished goods and merchandises sold	5,060,121,493,001	4,925,236,692,972
Cost of services rendered	11,869,413,412	22,702,320,667
Cost of investment properties sold	-	12,036,276,582
Provision/(reversal of provision) for obsolete inventories	20,404,051,308	(30,883,947,027)
<b>TOTAL</b>	<b>5,092,394,957,721</b>	<b>4,929,091,343,194</b>

**26. FINANCE EXPENSES**

	Currency: VND	
	Current year	Previous year
Interest expenses	67,308,431,064	53,512,208,376
Foreign exchange losses	33,304,619,820	53,516,725,008
Provision/(reversal of provision) of financial investments	20,035,651,626	(3,321,928,600)
Others	114,800,000	-
<b>TOTAL</b>	<b>120,763,502,510</b>	<b>103,707,004,784</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

## 27. SELLING EXPENSES AND GENERAL AND ADMINISTRATIVE EXPENSES

	Currency: VND	
	Current year	Previous year
<b>Selling expenses incurred during the year</b>		
- Labour costs	143,271,901,925	139,897,631,200
- Raw material costs	6,436,707,330	8,014,016,313
- Expenses for external services	41,634,734,617	47,361,177,458
- Depreciation and amortization of fixed assets	19,151,516,283	20,175,184,369
- Others	66,709,203,499	58,523,986,206
<b>TOTAL</b>	<b>277,204,063,654</b>	<b>273,971,995,546</b>
<b>General and administrative expenses incurred during the year</b>		
- Labour costs	45,961,645,158	35,342,732,489
- Office equipment	2,943,648,175	3,899,140,722
- Depreciation and amortization of fixed assets	5,610,542,693	5,868,717,895
- Expenses for external services	24,755,650,452	30,659,935,952
- Provision for doubtful debts	18,206,616,741	11,124,256,486
- Taxes and fees	10,944,123,808	11,350,101,311
- Others	25,198,805,927	50,723,740,033
<b>TOTAL</b>	<b>133,621,032,954</b>	<b>148,968,624,888</b>

## 28. PRODUCTION AND OPERATING COSTS

	Currency: VND	
	Current year	Previous year
Costs of merchandises sold	5,025,630,709,084	4,844,326,237,181
Cost of investment properties sold	-	12,036,276,582
Raw materials expenses	54,532,708,326	42,693,615,702
Labour costs	196,308,561,115	182,805,414,346
Depreciation of fixed assets	28,797,277,868	30,171,329,873
Expenses for external services	73,219,608,011	90,717,715,816
Others	126,622,027,975	135,854,967,542
<b>TOTAL</b>	<b>5,505,110,892,379</b>	<b>5,338,605,557,042</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

29. OTHER INCOME AND EXPENSES

	Currency: VND	
	Current year	Previous year
<b>Other income</b>		
Insurance compensation	40,660,739,377	29,284,171,524
Gains from disposal of assets	1,081,593,838	1,845,182,325
Others	1,772,348,683	1,103,675,346
	<u>43,514,681,898</u>	<u>32,233,029,195</u>
<b>Other expenses</b>		
Penalties	5,682,332,846	4,543,624,166
Others	1,436,557,226	1,515,967,181
	<u>7,118,890,072</u>	<u>6,059,591,347</u>
<b>NET OTHER PROFIT</b>	<u><b>36,395,791,826</b></u>	<u><b>26,173,437,848</b></u>

30. CORPORATE INCOME TAX

The statutory corporate income tax ("CIT") applicable to the Corporation and its subsidiaries is 20% of taxable income.

Tax returns of the Corporation and its subsidiaries will be subject to examination by the tax authorities. As the application of tax laws and regulations to different types of operations may be explained in different ways, the amounts reported in the consolidated financial statements could change at a later date upon final determination by the tax authorities.

30.1 CIT expenses

	Currency: VND	
	Current year	Previous year
Current CIT expenses	31,879,281,718	37,257,614,229
Deferred tax expenses	2,087,087,846	3,879,165,953
<b>TOTAL</b>	<u><b>33,966,369,564</b></u>	<u><b>41,136,780,182</b></u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**30. CORPORATE INCOME TAX (continued)**

**30.2 Current CIT expenses**

The current tax payable is based on taxable income for the current year. The taxable income of the Corporation and its subsidiaries for the year differs from the profit as reported in the consolidated income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are not taxable or deductible. The Corporation and its subsidiaries' liabilities for current tax is calculated using tax rates that have been enacted by the balance sheet date.

The reconciliation between the profit before tax and taxable profit is presented below:

	Currency: VND	
	Current year	Previous year
<b>Accounting profit before tax</b>	<b>824,782,295,997</b>	<b>509,231,906,937</b>
<i>Adjustments to increase:</i>		
Non-deductible expenses	3,374,211,441	3,337,858,606
Allowance for non-executive members of the Board of Directors and Board of Supervisors	1,693,660,000	977,936,364
Others	1,692,678,012	17,718,424,462
<i>Adjustments to decrease:</i>		
Dividend income	(147,130,720,686)	(162,671,888,300)
Reversal of provision for inventories	-	(8,419,675,876)
Reversal of provision for doubtful debts	(1,113,406,730)	-
Reversal of provision for investments	(9,867,396,125)	-
Other adjustments	(5,247,422,167)	(5,846,720,627)
Effects of the elimination of intra-group transactions for consolidation purpose	(504,373,883,112)	(159,475,526,247)
Loss carried forward	-	(3,555,112,852)
<b>Estimated current taxable income</b>	<b>163,810,016,630</b>	<b>191,297,202,467</b>
<i>In which:</i>		
Income subject to tax rate of 20%	169,831,847,820	196,786,973,714
Tax losses	(6,021,831,190)	(5,489,771,247)
<b>Estimated current CIT expenses</b>	<b>33,966,369,564</b>	<b>39,357,394,743</b>
Adjustment for under accrual of tax from prior years	-	1,779,385,439
<b>Current CIT expenses</b>	<b>33,966,369,564</b>	<b>41,136,780,182</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**30. CORPORATE INCOME TAX (continued)**

**30.3 Deferred tax**

The following are the deferred tax assets recognized by the Corporation's subsidiary, and the movements thereon, during the current and previous years.

Currency: VND

	<i>Consolidated balance sheet</i>		<i>Consolidated income statement</i>	
	<i>Ending balance</i>	<i>Beginning balance</i>	<i>Current year</i>	<i>Previous year</i>
<b>Deferred tax assets</b>				
Provision for obsolete inventories	1,612,674,572	4,615,812,818	(3,003,138,246)	(3,879,165,953)
Bonus accruals	900,000,000	-	900,000,000	-
Others	16,050,400	-	16,050,400	-
	<b>2,528,724,972</b>	<b>4,615,812,818</b>		
<b>Net deferred tax charged to consolidated income statement</b>			<b>(2,087,087,846)</b>	<b>(3,879,165,953)</b>

**30.4 Unrecognized deferred tax assets**

**Tax losses carried forward**

The Corporation and its subsidiaries are entitled to carry tax losses forward to offset against taxable income arising within five years subsequent to the year in which the loss was incurred. At the balance sheet date, the Corporation has aggregated accumulated tax losses that can be used to offset against future taxable income. Details are as follows:

Currency: VND

<i>Originating year</i>	<i>Can be utilized up to</i>	<i>Tax loss amount (*)</i>	<i>Utilized up to 31 December 2025</i>	<i>Forfeited</i>	<i>Unutilized at 31 December 2025</i>
2020	2025	(29,191,275,856)	3,459,226,496	-	(25,732,049,360)
2022	2027	(88,028,387,898)	-	-	(88,028,387,898)
2023	2028	(3,779,186,948)	-	-	(3,779,186,948)
2025	2030	(6,021,831,190)	-	-	(6,021,831,190)
<b>TOTAL</b>		<b>(127,020,681,892)</b>	<b>3,459,226,496</b>	<b>-</b>	<b>(123,561,455,396)</b>

These are the estimated tax losses as per the corporate income tax declarations of the Corporation which have not been audited by the tax authorities as of the date of these consolidated financial statements.

The Corporation has not recognized deferred tax assets for these accumulated tax losses due to the uncertainty of future taxable profit at this stage.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**31. TRANSACTIONS WITH RELATED PARTIES**

The list of related parties over which the Corporation and its subsidiaries have control/significant influence and other related parties that have significant transactions with the Corporation and its subsidiaries during the year and as at 31 December 2025 includes:

<i>No.</i>	<i>Related parties</i>	<i>Relationship</i>
1	State Capital Investment Corporation	Major shareholder
2	Vietnam Medical Products Import - Export Joint Stock Company	Associate
3	Sanofi Vietnam Joint Stock Company	Associate from 6 October 2025
4	Sanofi-Synthelabo Vietnam Pharmaceutical Joint Stock Company	Associate
5	Central Pharmaceutical Joint Stock Company No.25	Associate
6	Danapha Pharmaceutical Joint Stock Company	Associate
7	Davina Pharmaceutical Joint Stock Company	Associate
8	Central Pharmaceutical Joint Stock Company No.03	Associate
9	Imexpharm Pharmaceutical Joint Stock Company	Associate
10	Vietnam Alfresa Codupha Medical Company Limited	Associate
11	Mekophar Chemical – Pharmaceutical Joint Stock Company	Entity with a mutual member of Board of Directors ("BoD") and key management until 24 April 2025
12	OPC Pharmaceutical Joint Stock Company	Entity with a mutual member of BoD
13	Ms. Lu Thi Khanh Tran	Chief Accountant

The list of related individuals who are members of the Board of Directors, the Management and the Internal Audit is presented in the General Information section of the consolidated financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**31. TRANSACTIONS WITH RELATED PARTIES** (continued)

Significant transactions of the Corporation and its subsidiaries with related parties in current year and previous year were as follows:

		<i>Currency: VND</i>	
<i>Related party</i>	<i>Transactions</i>	<i>Current year</i>	<i>Previous year</i>
State Capital Investment Corporation	Dividends paid	154,050,000,000	107,835,000,000
Vietnam Medical Products Import - Export Joint Stock Company	Dividends received	1,485,000,000	1,485,000,000
	Storage fees	-	131,790,387
	Revenue from sale of goods	42,753,420	-
Sanofi Vietnam Joint Stock Company	Revenue from trademark royalties	127,500,000,000	118,500,000,000
	Purchase of shares	494,000,000,000	-
Sanofi-Synthelabo Vietnam Pharmaceutical Shareholding Company	Dividends received	95,998,720,000	-
Danapha Pharmaceutical Joint Stock Company	Dividends received	-	3,876,716,900
	Revenue from medical testing services	-	2,205,002,096
	Revenue from trademark royalties	105,407,191	196,826,169
Central Pharmaceutical Joint Stock Company No.3	Dividends received	14,238,261,000	14,238,261,000
	Purchases of goods	-	305,174,992
	Trademark royalties fee	47,308,387	28,179,317
Imexpharm Corporation	Dividends received	16,974,496,000	15,431,360,000
	Purchase of goods and services	16,195,042,500	3,033,988,980
	Revenue from sales of goods	1,887,500	-
	Revenue from medical testing services	-	304,761,905
Mekophar Chemical – Pharmaceutical Joint Stock Company	Dividends received	2,328,717,500	2,328,717,500
OPC Pharmaceutical Joint Stock Company	Dividends received	-	12,878,979,000
	Purchases of goods and services	17,275,574,376	9,250,972,772
	Revenue from goods and services	-	110,751,500
	Revenue from trademark royalties	43,501,556	43,313,000

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

31. TRANSACTIONS WITH RELATED PARTIES (continued)

*Terms and conditions of transactions with related parties*

The sales to and purchases from related parties are made based on contractual agreement.

The Corporation recognized royalty revenue from "Cao Sao Vang" trademark with related parties based on contractual agreement.

Outstanding balances at 31 December 2025 are unsecured, interest free and will be settled in cash. For the year ended 31 December 2025, the Corporation and its subsidiaries have not made any provision for doubtful debts relating to amounts owed by related parties (31 December 2024: VND 0). This assessment is undertaken each financial year through the examination of the financial position of the related party and the market in which the related party operates.

Amounts due to and due from related parties at the balance sheet dates were as follows:

Currency: VND			
<i>Related party</i>	<i>Transactions</i>	<i>Ending balance</i>	<i>Beginning balance</i>
<b>Short-term trade payables (Note 16.1)</b>			
Danapha Pharmaceutical Joint Stock Company	Purchases of goods	-	2,512,937
Central Pharmaceutical Joint Stock Company No.3	Purchases of goods	190,081,584	310,250,799
Vietnam Alfresa Codupha Medical Company Limited	Purchases of goods	875,553,313	986,099,722
OPC Pharmaceutical Joint Stock Company	Purchases of goods	9,021,725,182	6,720,946,735
<b>TOTAL</b>		<b>10,087,360,079</b>	<b>8,019,810,193</b>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

31. TRANSACTIONS WITH RELATED PARTIES (continued)

*Transactions with other related parties*

Salary and allowances to members of the Board of Directors, the Management and Chief Accountant (including salary and allowances in subsidiaries) during the year:

Currency: VND

<i>Individuals</i>	<i>Salary and allowances</i>	
	<i>Current year</i>	<i>Previous year</i>
Mr. Dinh Xuan Han	1,319,110,000	1,076,386,364
Mr. Nguyen Tien Dung	125,869,565	-
Mr. Tran Duc Hung	54,130,435	161,363,636
Ms. Han Thi Khanh Vinh	1,615,000,000	1,038,500,000
Mr. Do Manh Cuong	180,000,000	124,090,909
Mr. Tran Van Hai	120,000,000	120,000,000
Ms. Nguyen Hong Nhung	-	216,931,818
Ms. Pham Thi Xuan Huong	-	37,727,273
Ms. Lu Thi Khanh Tran	779,000,000	774,000,000
<b>TOTAL</b>	<b>4,193,110,000</b>	<b>3,549,000,000</b>

Salaries and operating expenses of the Board of Supervisors:

Currency: VND

	<i>Current year</i>	<i>Previous year</i>
Salaries and operating expenses of the Board of Supervisors	-	237,048,182

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

### 32. EARNINGS PER SHARE

The following reflects the income and share data used in the basic and diluted earnings per share computations:

	Currency: VND	
	Current year	Previous year (Restated)
Profit after tax	738,599,083,818	420,814,703,639
Adjustment due to appropriation to bonus and welfare fund	(10,806,007,393)	(15,469,246,367)
<b>Net profit after tax attributable to ordinary shareholders</b>	<b><u>727,793,076,425</u></b>	<b><u>405,345,457,272</u></b>
Weighted average number of ordinary shares (excluding treasury shares) for basic earnings per share	<u>237,000,000</u>	<u>237,000,000</u>
<b>Weighted average number of ordinary shares (excluding treasury shares) adjusted for the effect of dilution</b>	<b><u>237,000,000</u></b>	<b><u>237,000,000</u></b>
<b>Earnings per share</b>		
- Basic	3,071	1,710
- Diluted	3,071	1,710

Profit used to compute earnings per share for the year ended 31 December 2024 was adjusted for the provisional appropriation to bonus and welfare fund from 2024's profit in accordance with the Resolution of the General Meeting of Shareholders of the Corporation and its subsidiaries.

Net profit used to compute earnings per share for the year ended 31 December 2025 was also adjusted for the amount of bonus and welfare fund that is expected to be appropriated from the profit for the year 2025 following the profit distribution plan for the year 2025 as approved in the Resolution of the General Meeting of Shareholders of the Corporation's subsidiaries. This net profit amount does not include adjustments for the amount of bonus and welfare fund that is expected to be appropriated from the profit for the year 2025 of the Corporation since there has not been any plan of bonus and welfare fund distribution for the year 2025.

There are no other common stock transactions or other potential common stock transactions occurring from the balance sheet date to the date of completion of these consolidated financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

### 33. COMMITMENTS

#### *Operating lease commitment as a lessee*

The Corporation and its subsidiaries currently lease assets under operating lease arrangements. The future minimum lease commitments as at the balance sheet dates under these operating lease agreements are as follows:

	Currency: VND	
	Ending balance	Beginning balance
Under 1 year	21,995,124,155	22,346,811,252
From 1 to 5 years	98,214,146,600	78,574,346,942
Over 5 years	371,705,026,140	291,868,562,959
<b>TOTAL</b>	<b>491,914,296,895</b>	<b>392,789,721,153</b>

#### *Operating lease commitment as a lessor*

The Corporation and its subsidiaries currently let out assets under operating leases arrangements. The future minimum rental receivable as at the balance sheet dates under these operating lease agreements are as follows:

	Currency: VND	
	Ending balance	Beginning balance
Under 1 year	14,151,556,239	8,034,289,326
From 1 to 5 years	23,339,211,122	12,578,879,986
<b>TOTAL</b>	<b>37,490,767,361</b>	<b>20,613,169,312</b>

### 34. EVENTS AFTER THE BALANCE SHEET DATE

There is no matter or circumstance that has arisen since the balance sheet date that requires adjustment or disclosure in the consolidated financial statements of the Corporation and its subsidiaries.

Hanoi, Vietnam  
30 March 2026

  
 \_\_\_\_\_  
 Nguyen Thi Hang  
Preparer

  
 \_\_\_\_\_  
 Lu Thi Khanh Tran  
Chief Accountant

  
  
 \_\_\_\_\_  
 Han Thi Khanh Vinh  
General Director

## EY | Building a better working world

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via [ey.com/privacy](https://ey.com/privacy). EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit [ey.com](https://ey.com).

© 2025 Ernst & Young Vietnam Limited. All Rights Reserved.

[ey.com/en\\_vn](https://ey.com/en_vn)